U.S. patent application number 14/147074 was filed with the patent office on 2014-05-01 for chlamydia antigens.
This patent application is currently assigned to President and Fellows of Harvard College. The applicant listed for this patent is President and Fellows of Harvard College. Invention is credited to Todd Gierahn, Darren E. HIGGINS.
Application Number | 20140120129 14/147074 |
Document ID | / |
Family ID | 40718416 |
Filed Date | 2014-05-01 |
United States Patent
Application |
20140120129 |
Kind Code |
A1 |
HIGGINS; Darren E. ; et
al. |
May 1, 2014 |
CHLAMYDIA ANTIGENS
Abstract
Chlamydia antigens (e.g., polypeptides, polypeptide fragments,
and fusion proteins) are provided. Also provided are vaccines and
pharmaceutical compositions for treating or preventing a bacterial
infection, such as Chlamydia, in a subject.
Inventors: |
HIGGINS; Darren E.; (Jamaica
Plain, MA) ; Gierahn; Todd; (Brookline, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
President and Fellows of Harvard College |
Cambridge |
MA |
US |
|
|
Assignee: |
President and Fellows of Harvard
College
Cambridge
MA
|
Family ID: |
40718416 |
Appl. No.: |
14/147074 |
Filed: |
January 3, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12746155 |
Jun 24, 2010 |
8637053 |
|
|
PCT/US08/13298 |
Dec 3, 2008 |
|
|
|
14147074 |
|
|
|
|
61005209 |
Dec 3, 2007 |
|
|
|
Current U.S.
Class: |
424/190.1 ;
530/350 |
Current CPC
Class: |
A61P 31/04 20180101;
A61P 37/04 20180101; A61K 2039/505 20130101; A61K 2039/53 20130101;
A61K 39/00 20130101; C07K 14/295 20130101 |
Class at
Publication: |
424/190.1 ;
530/350 |
International
Class: |
C07K 14/295 20060101
C07K014/295 |
Claims
1. An isolated CT491 polypeptide comprising an amino acid sequence
substantially identical to SEQ ID NO: 1, or fragment thereof,
wherein said polypeptide or fragment elicits at least an 40-fold
increase in interferon-.gamma. production from a population of
T-lymphocytes compared to the level of interferon-.gamma.
production elicited from a non-antigenic peptide in the same
assay.
2. The polypeptide or fragment of claim 1, wherein said polypeptide
or fragment, when administered to a mammal, elicits an immune
response.
3. The polypeptide or fragment of claim 1, wherein said polypeptide
or fragment elicits a CD8.sup.+ T-cell response.
4. The polypeptide or fragment of claim 1, wherein said polypeptide
or fragment comprises at least one flanking amino acid.
5. The fragment of claim 1, wherein said fragment is fewer than 400
amino acids in length.
6. The fragment of claim 5, wherein said fragment is fewer than 300
amino acids in length.
7. The fragment of claim 6, wherein said fragment is fewer than 200
amino acids in length.
8. The fragment of claim 7, wherein said fragment is fewer than 100
amino acids in length.
9. The fragment of claim 8, wherein said fragment is fewer than 50
amino acids in length.
10. The fragment of claim 9, wherein said fragment is fewer than 30
amino acids in length.
11. The fragment of claim 10, wherein said fragment is fewer than
15 amino acids in length.
12. The polypeptide or fragment of claim 1, wherein said
polypeptide or fragment contains at least one conservative amino
acid substitution in the sequence of SEQ ID NO: 1.
13. The polypeptide or fragment of claim 12, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
14. The polypeptide or fragment of claim 12, wherein said
polypeptide or fragment contains at least three conservative amino
acid substitutions in the sequence of SEQ ID NO: 1.
15. The polypeptide or fragment of claim 14, wherein said
polypeptide or fragment contains at least five conservative amino
acid substitutions in the sequence of SEQ ID NO: 1.
16. A pharmaceutical composition comprising the polypeptide or
fragment of claim 1 in a pharmaceutically acceptable carrier.
17. A vaccine comprising: a) the polypeptide or fragment of claim
1, and b) a pharmaceutically acceptable carrier.
18. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the polypeptide or fragment of
claim 1.
19. The method of claim 18, wherein said polypeptide or fragment is
in a pharmaceutically acceptable carrier.
20. The method of claim 18, wherein said polypeptide or fragment is
capable of generating an immune response in said subject.
21. The method of claim 18, wherein said bacterial infection is
Chlamydia infection.
22. The method of claim 21, wherein said subject has or is at risk
for contracting Chlamydia.
23. An isolated fusion protein comprising: a) the polypeptide or
fragment of claim 1; and b) a fusion partner.
24. The fusion protein of claim 23, wherein said fragment comprises
at least one flanking amino acid.
25. A pharmaceutical composition comprising the fusion protein of
claim 23 and a pharmaceutically acceptable carrier.
26. A vaccine comprising: a) the fusion protein of claim 23, and b)
a pharmaceutically acceptable carrier.
27. A DNA vaccine comprising a polynucleotide sequence that encodes
the polypeptide or fragment of claim 1.
28. A DNA vaccine comprising a polynucleotide sequence that encodes
the fusion protein of claim 23.
29. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 27 or
28.
30. The method of claim 29, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
31. The method of claim 29, wherein said DNA vaccine is capable of
generating an immune response in said subject.
32. The method of claim 29, wherein said bacterial infection is
Chlamydia infection.
33. The method of claim 32, wherein said subject has or is at risk
for contracting Chlamydia.
34. An isolated CT601 polypeptide comprising an amino acid sequence
substantially identical to SEQ ID NO: 2, or fragment thereof,
wherein said polypeptide or fragment elicits at least an 40-fold
increase in interferon-.gamma. production from a population of
T-lymphocytes compared to the level of interferon-.gamma.
production elicited from a non-antigenic peptide in the same
assay.
35. The polypeptide or fragment of claim 34, wherein said
polypeptide or fragment, when administered to a mammal, elicits an
immune response.
36. The polypeptide or fragment of claim 34, wherein said
polypeptide or fragment elicits a CD8.sup.+ T-cell response.
37. The polypeptide or fragment of claim 34, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
38. The fragment of claim 34, wherein said fragment is fewer than
150 amino acids in length.
39. The fragment of claim 38, wherein said fragment is fewer than
100 amino acids in length.
40. The fragment of claim 39, wherein said fragment is fewer than
50 amino acids in length.
41. The fragment of claim 40, wherein said fragment is fewer than
30 amino acids in length.
42. The fragment of claim 41, wherein said fragment is fewer than
15 amino acids in length.
43. The polypeptide or fragment of claim 34, wherein said
polypeptide or fragment contains at least one conservative amino
acid substitution in the sequence of SEQ ID NO: 2.
44. The polypeptide or fragment of claim 43, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
45. The polypeptide or fragment of claim 43, wherein said
polypeptide or fragment at least three conservative amino acid
substitutions in the sequence of SEQ ID NO: 2.
46. The polypeptide or fragment of claim 45, wherein said
polypeptide or fragment contains at least five conservative amino
acid substitutions in the sequence of SEQ ID NO: 2.
47. A pharmaceutical composition comprising the polypeptide or
fragment of claim 34 in a pharmaceutically acceptable carrier.
48. A vaccine comprising: a) the polypeptide or fragment of claim
34, and b) a pharmaceutically acceptable carrier.
49. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the polypeptide or fragment of
claim 34.
50. The method of claim 49, wherein said polypeptide or fragment is
in a pharmaceutically acceptable carrier.
51. The method of claim 49, wherein said polypeptide or fragment is
capable of generating an immune response in said subject.
52. The method of claim 49, wherein said bacterial infection is
Chlamydia infection.
53. The method of claim 52, wherein said subject has or is at risk
for contracting Chlamydia.
54. An isolated fusion protein comprising: a) the polypeptide or
fragment of claim 34; and b) a fusion partner.
55. The fusion protein of claim 54, wherein said fragment comprises
at least one flanking amino acid.
56. A pharmaceutical composition comprising the fusion protein of
claim 54 and a pharmaceutically acceptable carrier.
57. A vaccine comprising: a) the fusion protein of claim 54, and b)
a pharmaceutically acceptable carrier.
58. A DNA vaccine comprising a polynucleotide sequence that encodes
the polypeptide or fragment of claim 34.
59. A DNA vaccine comprising a polynucleotide sequence that encodes
the fusion protein of claim 54.
60. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 58 or
59.
61. The method of claim 60, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
62. The method of claim 60, wherein said DNA vaccine is capable of
generating an immune response in said subject.
63. The method of claim 60, wherein said bacterial infection is
Chlamydia infection.
64. The method of claim 63, wherein said subject has or is at risk
for contracting Chlamydia.
65. An isolated CT687 polypeptide comprising an amino acid sequence
substantially identical to SEQ ID NO: 3, or fragment thereof,
wherein said polypeptide or fragment elicits at least an 40-fold
increase in interferon-.gamma. production from a population of
T-lymphocytes compared to the level of interferon-.gamma.
production elicited from a non-antigenic peptide in the same
assay.
66. The polypeptide or fragment of claim 65, wherein said
polypeptide or fragment, when administered to a mammal, elicits an
immune response.
67. The polypeptide or fragment of claim 65, wherein said
polypeptide or fragment elicits a CD8.sup.+ T-cell response.
68. The polypeptide or fragment of claim 65, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
69. The fragment of claim 65, wherein said fragment is fewer than
400 amino acids in length.
70. The fragment of claim 69, wherein said fragment is fewer than
300 amino acids in length.
71. The fragment of claim 70, wherein said fragment is fewer than
200 amino acids in length.
72. The fragment of claim 71, wherein said fragment is fewer than
100 amino acids in length.
73. The fragment of claim 72, wherein said fragment is fewer than
50 amino acids in length.
74. The fragment of claim 73, wherein said fragment is fewer than
30 amino acids in length.
75. The fragment of claim 74, wherein said fragment is fewer than
15 amino acids in length.
76. The polypeptide or fragment of claim 65, wherein said
polypeptide or fragment contains at least one conservative amino
acid substitution in the sequence of SEQ ID NO: 3.
77. The polypeptide or fragment of claim 76, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
78. The polypeptide or fragment of claim 76, wherein said
polypeptide or fragment at least three conservative amino acid
substitutions in the sequence of SEQ ID NO: 3.
79. The polypeptide or fragment of claim 78, wherein said
polypeptide or fragment contains at least five conservative amino
acid substitutions in the sequence of SEQ ID NO: 3.
80. A pharmaceutical composition comprising the polypeptide or
fragment of claim 65 in a pharmaceutically acceptable carrier.
81. A vaccine comprising: a) the polypeptide or fragment of claim
65, and b) a pharmaceutically acceptable carrier.
82. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the polypeptide or fragment of
claim 65.
83. The method of claim 82, wherein said polypeptide or fragment is
in a pharmaceutically acceptable carrier.
84. The method of claim 82, wherein said polypeptide or fragment is
capable of generating an immune response in said subject.
85. The method of claim 82, wherein said bacterial infection is
Chlamydia infection.
86. The method of claim 85, wherein said subject has or is at risk
for contracting Chlamydia.
87. An isolated fusion protein comprising: a) the polypeptide or
fragment of claim 65; and b) a fusion partner.
88. The fusion protein of claim 87, wherein said fragment comprises
at least one flanking amino acid.
89. A pharmaceutical composition comprising the fusion protein of
claim 87 and a pharmaceutically acceptable carrier.
90. A vaccine comprising: a) the fusion protein of claim 87, and b)
a pharmaceutically acceptable carrier.
91. A DNA vaccine comprising a polynucleotide sequence that encodes
the polypeptide or fragment of claim 65.
92. A DNA vaccine comprising a polynucleotide sequence that encodes
the fusion protein of claim 87.
93. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 91 or
92.
94. The method of claim 93, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
95. The method of claim 93, wherein said DNA vaccine is capable of
generating an immune response in said subject.
96. The method of claim 93, wherein said bacterial infection is
Chlamydia infection.
97. The method of claim 96, wherein said subject has or is at risk
for contracting Chlamydia.
98. An isolated CT732 polypeptide comprising an amino acid sequence
substantially identical to SEQ ID NO: 4, or fragment thereof,
wherein said polypeptide or fragment elicits at least an 40-fold
increase in interferon-.gamma. production from a population of
T-lymphocytes compared to the level of interferon-.gamma.
production elicited from a non-antigenic peptide in the same
assay.
99. The polypeptide or fragment of claim 98, wherein said
polypeptide or fragment, when administered to a mammal, elicits an
immune response.
100. The polypeptide or fragment of claim 98, wherein said
polypeptide or fragment elicits a CD8.sup.+ T-cell response.
101. The polypeptide or fragment of claim 98, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
102. The fragment of claim 98, wherein said fragment is fewer than
150 amino acids in length.
103. The fragment of claim 102, wherein said fragment is fewer than
100 amino acids in length.
104. The fragment of claim 103, wherein said fragment is fewer than
50 amino acids in length.
105. The fragment of claim 104, wherein said fragment is fewer than
30 amino acids in length.
106. The fragment of claim 105, wherein said fragment is fewer than
15 amino acids in length.
107. The polypeptide or fragment of claim 98, wherein said
polypeptide or fragment contains at least one conservative amino
acid substitution in the sequence of SEQ ID NO: 4.
108. The polypeptide or fragment of claim 107, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
109. The polypeptide or fragment of claim 107, wherein said
polypeptide or fragment contains at least three conservative amino
acid substitutions in the sequence of SEQ ID NO: 4.
110. The polypeptide or fragment of claim 109, wherein said
polypeptide or fragment contains at least five conservative amino
acid substitutions in the sequence of SEQ ID NO: 4.
111. A pharmaceutical composition comprising the polypeptide or
fragment of claim 98 in a pharmaceutically acceptable carrier.
112. A vaccine comprising: a) the polypeptide or fragment of claim
98, and b) a pharmaceutically acceptable carrier.
113. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the polypeptide or fragment of
claim 98.
114. The method of claim 113, wherein said polypeptide or fragment
is in a pharmaceutically acceptable carrier.
115. The method of claim 113, wherein said polypeptide or fragment
is capable of generating an immune response in said subject.
116. The method of claim 113, wherein said bacterial infection is
Chlamydia infection.
117. The method of claim 116, wherein said subject has or is at
risk for contracting Chlamydia.
118. An isolated fusion protein comprising: a) the polypeptide or
fragment of claim 98; and b) a fusion partner.
119. The fusion protein of claim 118, wherein said fragment
comprises at least one flanking amino acid.
120. A pharmaceutical composition comprising the fusion protein of
claim 118 and a pharmaceutically acceptable carrier.
121. A vaccine comprising: a) the fusion protein of claim 118, and
b) a pharmaceutically acceptable carrier.
122. A DNA vaccine comprising a polynucleotide sequence that
encodes the polypeptide or fragment of claim 98.
123. A DNA vaccine comprising a polynucleotide sequence that
encodes the fusion protein of claim 118.
124. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 122 or
123.
125. The method of claim 124, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
126. The method of claim 124, wherein said DNA vaccine is capable
of generating an immune response in said subject.
127. The method of claim 124, wherein said bacterial infection is
Chlamydia infection.
128. The method of claim 127, wherein said subject has or is at
risk for contracting Chlamydia.
129. An isolated CT781 polypeptide comprising an amino acid
sequence substantially identical to SEQ ID NO: 5, or fragment
thereof, wherein said polypeptide or fragment elicits at least an
40-fold increase in interferon-.gamma. production from a population
of T-lymphocytes compared to the level of interferon-.gamma.
production elicited from a non-antigenic peptide in the same
assay.
130. The polypeptide or fragment of claim 129, wherein said
polypeptide or fragment, when administered to a mammal, elicits an
immune response.
131. The polypeptide or fragment of claim 129, wherein said
polypeptide or fragment elicits a CD8.sup.+ T-cell response.
132. The polypeptide or fragment of claim 129, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
133. The fragment of claim 129, wherein said fragment is fewer than
500 amino acids in length.
134. The fragment of claim 133, wherein said fragment is fewer than
400 amino acids in length.
135. The fragment of claim 134, wherein said fragment is fewer than
300 amino acids in length.
136. The fragment of claim 135, wherein said fragment is fewer than
200 amino acids in length.
137. The fragment of claim 136, wherein said fragment is fewer than
100 amino acids in length.
138. The fragment of claim 137, wherein said fragment is fewer than
50 amino acids in length.
139. The fragment of claim 138, wherein said fragment is fewer than
30 amino acids in length.
140. The fragment of claim 139, wherein said fragment is fewer than
15 amino acids in length.
141. The polypeptide or fragment of claim 129, wherein said
polypeptide or fragment contains at least one conservative amino
acid substitution in the sequence of SEQ ID NO: 5.
142. The polypeptide or fragment of claim 141, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
143. The polypeptide or fragment of claim 141, wherein said
polypeptide or fragment contains at least three conservative amino
acid substitutions in the sequence of SEQ ID NO: 5.
144. The polypeptide or fragment of claim 143, wherein said
polypeptide or fragment contains at least five conservative amino
acid substitutions in the sequence of SEQ ID NO: 5.
145. A pharmaceutical composition comprising the polypeptide or
fragment of claim 129 in a pharmaceutically acceptable carrier.
146. A vaccine comprising: a) the polypeptide or fragment of claim
129, and b) a pharmaceutically acceptable carrier.
147. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the polypeptide or fragment of
claim 129.
148. The method of claim 147, wherein said polypeptide or fragment
is in a pharmaceutically acceptable carrier.
149. The method of claim 147, wherein said polypeptide or fragment
is capable of generating an immune response in said subject.
150. The method of claim 147, wherein said bacterial infection is
Chlamydia infection.
151. The method of claim 150, wherein said subject has or is at
risk for contracting Chlamydia.
152. An isolated fusion protein comprising: a) the polypeptide or
fragment of claim 129; and b) a fusion partner.
153. The fusion protein of claim 152, wherein said fragment
comprises at least one flanking amino acid.
154. A pharmaceutical composition comprising the fusion protein of
claim 152 and a pharmaceutically acceptable carrier.
155. A vaccine comprising: a) the fusion protein of claim 152, and
b) a pharmaceutically acceptable carrier.
156. A DNA vaccine comprising a polynucleotide sequence that
encodes the polypeptide or fragment of claim 129.
157. A DNA vaccine comprising a polynucleotide sequence that
encodes the fusion protein of claim 152.
158. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 156 or
157.
159. The method of claim 158, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
160. The method of claim 158, wherein said DNA vaccine is capable
of generating an immune response in said subject.
161. The method of claim 158, wherein said bacterial infection is
Chlamydia infection.
162. The method of claim 161, wherein said subject has or is at
risk for contracting Chlamydia.
163. An isolated CT808 polypeptide comprising an amino acid
sequence substantially identical to SEQ ID NO: 6, or fragment
thereof, wherein said polypeptide or fragment elicits at least an
40-fold increase in interferon-.gamma. production from a population
of T-lymphocytes compared to the level of interferon-.gamma.
production elicited from a non-antigenic peptide in the same
assay.
164. The polypeptide or fragment of claim 163, wherein said
polypeptide or fragment, when administered to a mammal, elicits an
immune response.
165. The polypeptide or fragment of claim 163, wherein said
polypeptide or fragment elicits a CD8.sup.+ T-cell response.
166. The polypeptide or fragment of claim 163, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
167. The fragment of claim 163, wherein said fragment is fewer than
500 amino acids in length.
168. The fragment of claim 167, wherein said fragment is fewer than
400 amino acids in length.
169. The fragment of claim 168, wherein said fragment is fewer than
300 amino acids in length.
170. The fragment of claim 169, wherein said fragment is fewer than
200 amino acids in length.
171. The fragment of claim 170, wherein said fragment is fewer than
100 amino acids in length.
172. The fragment of claim 171, wherein said fragment is fewer than
50 amino acids in length.
173. The fragment of claim 172, wherein said fragment is fewer than
30 amino acids in length.
174. The fragment of claim 173, wherein said fragment is fewer than
15 amino acids in length.
175. The polypeptide or fragment of claim 163, wherein said
polypeptide or fragment contains at least one conservative amino
acid substitution in the sequence of SEQ ID NO: 6.
176. The polypeptide or fragment of claim 175, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
177. The polypeptide or fragment of claim 175, wherein said
polypeptide or fragment contains at least three conservative amino
acid substitutions in the sequence of SEQ ID NO: 6.
178. The polypeptide or fragment of claim 177, wherein said
polypeptide or fragment contains at least five conservative amino
acid substitutions in the sequence of SEQ ID NO: 6.
179. A pharmaceutical composition comprising the polypeptide or
fragment of claim 163 in a pharmaceutically acceptable carrier.
180. A vaccine comprising: a) the polypeptide or fragment of claim
163, and b) a pharmaceutically acceptable carrier.
181. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the polypeptide or fragment of
claim 163.
182. The method of claim 181, wherein said polypeptide or fragment
is in a pharmaceutically acceptable carrier.
183. The method of claim 181, wherein said polypeptide or fragment
is capable of generating an immune response in said subject.
184. The method of claim 181, wherein said bacterial infection is
Chlamydia infection.
185. The method of claim 184, wherein said subject has or is at
risk for contracting Chlamydia.
186. An isolated fusion protein comprising: a) the polypeptide or
fragment of claim 163; and b) a fusion partner.
187. The fusion protein of claim 186, wherein said fragment
comprises at least one flanking amino acid.
188. A pharmaceutical composition comprising the fusion protein of
claim 186 and a pharmaceutically acceptable carrier.
189. A vaccine comprising: a) the fusion protein of claim 186, and
b) a pharmaceutically acceptable carrier.
190. A DNA vaccine comprising a polynucleotide sequence that
encodes the polypeptide or fragment of claim 163.
191. A DNA vaccine comprising a polynucleotide sequence that
encodes the fusion protein of claim 186.
192. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 190 or
191.
193. The method of claim 192, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
194. The method of claim 192, wherein said DNA vaccine is capable
of generating an immune response in said subject.
195. The method of claim 192, wherein said bacterial infection is
Chlamydia infection.
196. The method of claim 195, wherein said subject has or is at
risk for contracting Chlamydia.
197. An isolated CT823 polypeptide comprising an amino acid
sequence substantially identical to SEQ ID NO: 7, or fragment
thereof, wherein said polypeptide or fragment elicits at least an
40-fold increase in interferon-.gamma. production from a population
of T-lymphocytes compared to the level of interferon-.gamma.
production elicited from a non-antigenic peptide in the same
assay.
198. The polypeptide or fragment of claim 197, wherein said
polypeptide or fragment, when administered to a mammal, elicits an
immune response.
199. The polypeptide or fragment of claim 197, wherein said
polypeptide or fragment elicits a CD8.sup.+ T-cell response.
200. The polypeptide or fragment of claim 197, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
201. The fragment of claim 197, wherein said fragment is fewer than
400 amino acids in length.
202. The fragment of claim 201, wherein said fragment is fewer than
300 amino acids in length.
203. The fragment of claim 202, wherein said fragment is fewer than
200 amino acids in length.
204. The fragment of claim 203, wherein said fragment is fewer than
100 amino acids in length.
205. The fragment of claim 204, wherein said fragment is fewer than
50 amino acids in length.
206. The fragment of claim 205, wherein said fragment is fewer than
30 amino acids in length.
207. The fragment of claim 206, wherein said fragment is fewer than
15 amino acids in length.
208. The polypeptide or fragment of claim 197, wherein said
polypeptide or fragment contains at least one conservative amino
acid substitution in the sequence of SEQ ID NO: 7.
209. The polypeptide or fragment of claim 208, wherein said
polypeptide or fragment comprises at least one flanking amino
acid.
210. The polypeptide or fragment of claim 208, wherein said
polypeptide or fragment contains at least three conservative amino
acid substitutions in the sequence of SEQ ID NO: 7.
211. The polypeptide or fragment of claim 210, wherein said
polypeptide or fragment contains at least five conservative amino
acid substitutions in the sequence of SEQ ID NO: 7.
212. A pharmaceutical composition comprising the polypeptide or
fragment of claim 197 in a pharmaceutically acceptable carrier.
213. A vaccine comprising: a) the polypeptide or fragment of claim
197, and b) a pharmaceutically acceptable carrier.
214. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the polypeptide or fragment of
claim 197.
215. The method of claim 214, wherein said polypeptide or fragment
is in a pharmaceutically acceptable carrier.
216. The method of claim 214, wherein said polypeptide or fragment
is capable of generating an immune response in said subject.
217. The method of claim 214, wherein said bacterial infection is
Chlamydia infection.
218. The method of claim 217, wherein said subject has or is at
risk for contracting Chlamydia.
219. An isolated fusion protein comprising: a) the polypeptide or
fragment of claim 197; and b) a fusion partner.
220. The fusion protein of claim 219, wherein said fragment
comprises at least one flanking amino acid.
221. A pharmaceutical composition comprising the fusion protein of
claim 219 and a pharmaceutically acceptable carrier.
222. A vaccine comprising: a) the fusion protein of claim 219, and
b) a pharmaceutically acceptable carrier.
223. A DNA vaccine comprising a polynucleotide sequence that
encodes the polypeptide or fragment of claim 197.
224. A DNA vaccine comprising a polynucleotide sequence that
encodes the fusion protein of claim 219.
225. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 223 or
224.
226. The method of claim 225, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
227. The method of claim 225, wherein said DNA vaccine is capable
of generating an immune response in said subject.
228. The method of claim 225, wherein said bacterial infection is
Chlamydia infection.
229. The method of claim 228, wherein said subject has or is at
risk for contracting Chlamydia.
230. An isolated CT062 polypeptide comprising an amino acid
sequence substantially identical to SEQ ID NO: 8, wherein said
polypeptide elicits at least an 40-fold increase interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-antigenic
peptide in the same assay.
231. The polypeptide of claim 230, wherein said polypeptide, when
administered to a mammal, elicits an immune response.
232. The polypeptide of claim 230, wherein said polypeptide elicits
a CD8.sup.+ T-cell response.
233. The polypeptide claim 230, wherein said polypeptide comprises
at least one flanking amino acid.
234. The polypeptide of claim 230, wherein said polypeptide
contains at least one conservative amino acid substitution in the
sequence of SEQ ID NO: 8.
235. The polypeptide of claim 234, wherein said polypeptide
comprises at least one flanking amino acid.
236. The polypeptide claim 234, wherein said polypeptide contains
at least three conservative amino acid substitutions in the
sequence of SEQ ID NO: 8.
237. The polypeptide of claim 236, wherein said polypeptide
contains at least five conservative amino acid substitutions in the
sequence of SEQ ID NO: 8.
238. A pharmaceutical composition comprising the polypeptide of
claim 230 in a pharmaceutically acceptable carrier.
239. A vaccine comprising: a) the polypeptide of claim 230, and b)
a pharmaceutically acceptable carrier.
240. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the polypeptide of claim
230.
241. The method of claim 240, wherein said polypeptide is in a
pharmaceutically acceptable carrier.
242. The method of claim 240, wherein said polypeptide is capable
of generating an immune response in said subject.
243. The method of claim 240, wherein said bacterial infection is
Chlamydia infection.
244. The method of claim 243, wherein said subject has or is at
risk for contracting Chlamydia.
245. An isolated fusion protein comprising: a) the polypeptide of
claim 230; and b) a fusion partner.
246. The fusion protein of claim 245, wherein said polypeptide
comprises at least one flanking amino acid.
247. A pharmaceutical composition comprising the fusion protein of
claim 245 and a pharmaceutically acceptable carrier.
248. A vaccine comprising: a) the fusion protein of claim 245, and
b) a pharmaceutically acceptable carrier.
249. A DNA vaccine comprising a polynucleotide sequence that
encodes the polypeptide of claim 230.
250. A DNA vaccine comprising a polynucleotide sequence that
encodes the fusion protein of claim 245.
251. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 249 or
250.
252. The method of claim 251, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
253. The method of claim 251, wherein said DNA vaccine is capable
of generating an immune response in said subject.
254. The method of claim 251, wherein said bacterial infection is
Chlamydia infection.
255. The method of claim 254, wherein said subject has or is at
risk for contracting Chlamydia.
256. An isolated CT062 fragment comprising an amino acid sequence
substantially identical to SEQ ID NO: 9, wherein said fragment
elicits at least an 40-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-antigenic
peptide in the same assay.
257. The fragment of claim 256, wherein said fragment, when
administered to a mammal, elicits an immune response.
258. The fragment of claim 256, wherein said fragment elicits a
CD8.sup.+ T-cell response.
259. The fragment of claim 256, wherein said fragment comprises at
least one flanking amino acid.
260. The fragment of claim 256, wherein said fragment is fewer than
300 amino acids in length.
261. The fragment of claim 260, wherein said fragment is fewer than
200 amino acids in length.
262. The fragment of claim 261, wherein said fragment is fewer than
100 amino acids in length.
263. The fragment of claim 262, wherein said fragment is fewer than
50 amino acids in length.
264. The fragment of claim 263, wherein said fragment is fewer than
30 amino acids in length.
265. The fragment of claim 264, wherein said fragment is fewer than
15 amino acids in length.
266. The fragment of claim 256, wherein said fragment contains at
least one conservative amino acid substitution in the sequence of
SEQ ID NO: 9.
267. The fragment of claim 266, wherein said fragment comprises at
least one flanking amino acid.
268. The fragment of claim 266, wherein said fragment contains at
least three conservative amino acid substitutions in the sequence
of SEQ ID NO: 9.
269. The fragment of claim 268, wherein said fragment contains at
least five conservative amino acid substitutions in the sequence of
SEQ ID NO: 9.
270. A pharmaceutical composition comprising the fragment of claim
256 in a pharmaceutically acceptable carrier.
271. A vaccine comprising: a) the fragment of claim 256, and b) a
pharmaceutically acceptable carrier.
272. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the fragment of claim 256.
273. The method of claim 272, wherein said fragment is in a
pharmaceutically acceptable carrier.
274. The method of claim 272, wherein said fragment is capable of
generating an immune response in said subject.
275. The method of claim 272, wherein said bacterial infection is
Chlamydia infection.
276. The method of claim 275, wherein said subject has or is at
risk for contracting Chlamydia.
277. An isolated fusion protein comprising: a) the fragment of
claim 256; and b) a fusion partner.
278. The fusion protein of claim 277, wherein said fragment
comprises at least one flanking amino acid.
279. A pharmaceutical composition comprising the fusion protein of
claim 277 and a pharmaceutically acceptable carrier.
280. A vaccine comprising: a) the fusion protein of claim 277, and
b) a pharmaceutically acceptable carrier.
281. A DNA vaccine comprising a polynucleotide sequence that
encodes the fragment of claim 256.
282. A DNA vaccine comprising a polynucleotide sequence that
encodes the fusion protein of claim 277.
283. A method of treating or preventing a bacterial infection, said
method comprising administering to a subject in need thereof, a
therapeutically effective amount of the DNA vaccine of claim 281 or
282.
284. The method of claim 283, wherein said DNA vaccine is in a
pharmaceutically acceptable carrier.
285. The method of claim 283, wherein said DNA vaccine is capable
of generating an immune response in said subject.
286. The method of claim 283, wherein said bacterial infection is
Chlamydia infection.
287. The method of claim 286, wherein said subject has or is at
risk for contracting Chlamydia.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 12/746,155, filed Jun. 24, 2010, which is a U.S. National Stage
of International Application No. PCT/US2008/13298, filed Dec. 3,
2008, which, in turn, claims the benefit of U.S. Provisional
Application No. 61/005,209, filed Dec. 3, 2007, which are hereby
incorporated by reference in their entirety.
BACKGROUND OF THE INVENTION
[0002] Chlamydia trachomatis is an intracellular bacterial pathogen
that colonizes and infects oculogenital surfaces. Ocular infections
of Chlamydia trachomatis cause trachoma, a chronic follicular
conjunctivitis that results in scarring and blindness. The World
Health Organization (WHO) estimates that 300-500 million people
worldwide are afflicted by trachoma (Resnikoff et al., Bull. WHO
82:844-851, 2004), making it the most prevalent form of infectious
preventable blindness (Whitcher et al. Bull. WHO 79:214-221, 2001).
Urogenital infections are the leading cause of bacterial sexually
transmitted diseases (Division of STD Prevention, Sexually
Transmitted Disease Surveillance 1997, Centers Dis. Cont. Prev.,
Atlanta, 1998) in both developing and industrialized nations (WHO,
Global Prevalence and Incidence of Selected Curable Sexually
Transmitted Infections: Overview and Estimates, WHO, Geneva, 2001).
Moreover, sexually transmitted diseases are risk factors for the
transmission of HIV (Plummer et al., J. Infect. Dis. 163:233-239,
1991), infertility (Westrom et al., Sex. Trans. Dis. 19:185-192,
1991), and human papilloma virus-induced cervical neoplasia
(Anttila et al., J. Am. Med. Assoc. 285:47-51, 2001).
[0003] For all the above reasons, control of C. trachomatis
infections is an important public health goal.
SUMMARY OF THE INVENTION
[0004] The present invention features C. trachomatis antigens, and
the therapeutic uses of such antigens. The antigens of the present
invention may be used to treat or prevent Chlamydia infection in a
subject.
[0005] In a first aspect, the present invention provides an
isolated CT491 polypeptide containing a sequence substantially
identical SEQ ID NO: 1, or fragment thereof, which elicits at least
a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-,
90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0006] An additional aspect of the invention is an isolated
fragment of a CT491 polypeptide, which is fewer than 464, 460, 450,
440, 430, 420, 410, 400, 390, 380, 370, 360, 350, 340, 330, 320,
310, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190,
180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50,
40, 35, 30, 25, 20, or 15 amino acids in length and elicits at
least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-,
80-, 90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay. Desirable CT491 fragments have at least
7 amino acids and/or elicit a CD8.sup.+ T cell response.
[0007] A related embodiment of the invention provides an isolated
fragment of a CT491 polypeptide, which is (1) fewer than 464, 460,
450, 440, 430, 420, 410, 400, 390, 380, 370, 360, 350, 340, 330,
320, 310, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200,
190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60,
50, 40, 35, 30, 25, 20, or 15 amino acids in length; (2) contains
at least one, preferably at least 2, 3, 4, 5, 6, 7, 8, 9, or 10
conservative amino acid substitutions in the sequence of SEQ ID NO:
1; and (3) elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-,
30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase
in interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay.
[0008] An additional embodiment of the invention provides an
isolated fragment of a CT491 polypeptide, which is (1) fewer than
464, 460, 450, 440, 430, 420, 410, 400, 390, 380, 370, 360, 350,
340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230, 220,
210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80,
70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids in length; (2)
contains at least one, preferably at least 2, 3, 4, 5, 6, 7, 8, 9,
or 10 conservative amino acid substitutions in the sequence of SEQ
ID NO: 1 and/or has at least one flanking amino acid (e.g., 1, 2,
3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids) at the N- and/or
C-terminus of the sequence of SEQ ID NO: 1; and (3) elicits at
least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-,
80-, 90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0009] A second aspect of the present invention is an isolated
CT601 polypeptide containing a sequence substantially identical SEQ
ID NO: 2, or fragment thereof, which elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0010] An additional aspect of the invention is an isolated
fragment of a CT601 polypeptide, which is fewer than 200, 190, 180,
170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35,
30, 25, 20, or 15 amino acids in length and elicits at least a 3-,
4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-,
100-, 200-, or 500-fold increase in interferon-.gamma. production
from a population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay. Desirable CT601 fragments have at least
7 amino acids and/or elicit a CD8.sup.+ T cell response.
[0011] A related embodiment of the invention provides an isolated
fragment of a CT601 polypeptide, which is (1) fewer than 200, 190,
180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50,
40, 35, 30, 25, 20, or 15 amino acids in length; (2) contains at
least one, preferably at least 2, 3, 4, 5, 6, 7, 8, 9, or 10
conservative amino acid substitutions in the sequence of SEQ ID NO:
2; and (3) elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-,
30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase
in interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay.
[0012] An additional embodiment of the invention provides an
isolated fragment of a CT601 polypeptide, which is (1) fewer than
200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70,
60, 50, 40, 35, 30, 25, 20, or 15 amino acids in length; (2)
contains at least one, preferably at least 2, 3, 4, 5, 6, 7, 8, 9,
or 10 conservative amino acid substitutions in the sequence of SEQ
ID NO: 2 and/or has at least one flanking amino acid (e.g., 1, 2,
3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids) at the N- and/or
C-terminus of the sequence of SEQ ID NO: 2; and (3) elicits at
least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-,
80-, 90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0013] In a third aspect, the present invention provides an
isolated CT687 polypeptide containing a sequence substantially
identical SEQ ID NO: 3, or fragment thereof, which elicits at least
a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-,
90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0014] An additional aspect of the invention is an isolated
fragment of a CT687 polypeptide, which is fewer than 401, 400, 390,
380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260,
250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130,
120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino
acids in length and elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-,
20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold
increase in interferon-.gamma. production from a population of
T-lymphocytes compared to the level of interferon-.gamma.
production elicited from a non-immunogenic peptide in the same
assay. Desirable CT687 fragments have at least 7 amino acids and/or
elicit a CD8.sup.+ T cell response.
[0015] A related embodiment of the invention provides an isolated
fragment of a CT687 polypeptide, which is (1) fewer than 401, 400,
390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270,
260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140,
130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15
amino acids in length; (2) contains at least one, preferably at
least 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid
substitutions in the sequence of SEQ ID NO: 3; and (3) elicits at
least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-,
80-, 90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0016] An additional embodiment of the invention provides an
isolated fragment of a CT687 polypeptide, which is (1) fewer than
401, 400, 390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290,
280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160,
150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25,
20, or 15 amino acids in length; (2) contains at least one,
preferably at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative
amino acid substitutions in the sequence of SEQ ID NO: 3 and/or has
at least one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10 flanking amino acids) at the N- and/or C-terminus of the
sequence of SEQ ID NO: 3; and (3) elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0017] In a fourth aspect, the present invention provides an
isolated CT732 polypeptide containing a sequence substantially
identical SEQ ID NO: 4, or fragment thereof, which elicits at least
a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-,
90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0018] An additional aspect of the invention is an isolated
fragment of a CT732 polypeptide, which is fewer than 157, 150, 140,
130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15
amino acids in length and elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay. Desirable CT732 fragments have at least
7 amino acids and/or elicit a CD8.sup.+ T cell response.
[0019] A related embodiment of the invention provides an isolated
fragment of a CT732 polypeptide, which is (1) fewer than 157, 150,
140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or
15 amino acids in length; (2) contains at least one, preferably at
least 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid
substitutions in the sequence of SEQ ID NO: 4; and (3) elicits at
least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-,
80-, 90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0020] An additional embodiment of the invention provides an
isolated fragment of a CT732 polypeptide, which is (1) fewer than
157, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30,
25, 20, or 15 amino acids in length; (2) contains at least one,
preferably at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative
amino acid substitutions in the sequence of SEQ ID NO: 4 and/or has
at least one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10 flanking amino acids) at the N- and/or C-terminus of the
sequence of SEQ ID NO: 4; and (3) elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0021] In a fifth aspect, the present invention provides an
isolated CT781 polypeptide containing a sequence substantially
identical SEQ ID NO: 5, or fragment thereof, which elicits at least
a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-,
90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0022] An additional aspect of the invention is an isolated
fragment of a CT781 polypeptide, which is fewer than 526, 520, 510,
500, 490, 480, 470, 460, 450, 440, 430, 420, 410, 400, 390, 380,
370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250,
240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120,
110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids
in length and elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-,
30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase
in interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay. Desirable CT781
fragments have at least 7 amino acids and/or elicit a CD8.sup.+ T
cell response.
[0023] A related embodiment of the invention provides an isolated
fragment of a CT781 polypeptide, which is (1) fewer than 526, 520,
510, 500, 490, 480, 470, 460, 450, 440, 430, 420, 410, 400, 390,
380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260,
250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130,
120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino
acids in length; (2) contains at least one, preferably at least 2,
3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitutions in
the sequence of SEQ ID NO: 5; and (3) elicits at least a 3-, 4-,
5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0024] An additional embodiment of the invention provides an
isolated fragment of a CT781 polypeptide, which is (1) fewer than
526, 520, 510, 500, 490, 480, 470, 460, 450, 440, 430, 420, 410,
400, 390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280,
270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150,
140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or
amino acids in length; (2) contains at least one, preferably at
least 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid
substitutions in the sequence of SEQ ID NO: 5 and/or has at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
flanking amino acids) at the N- and/or C-terminus of the sequence
of SEQ ID NO: 5; and (3) elicits at least a 3-, 4-, 5-, 6-, 7-, 8-,
10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0025] In a sixth aspect, the present invention provides an
isolated CT808 polypeptide containing a sequence substantially
identical SEQ ID NO: 6, or fragment thereof, which elicits at least
a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-,
90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0026] An additional aspect of the invention is an isolated
fragment of a CT808 polypeptide, which is fewer than 512, 510, 500,
490, 480, 470, 460, 450, 440, 430, 420, 410, 400, 390, 380, 370,
360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240,
230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110,
100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids in
length and elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-,
30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase
in interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay. Desirable CT808
fragments have at least 7 amino acids and/or elicit a CD8.sup.+ T
cell response.
[0027] A related embodiment of the invention provides an isolated
fragment of a CT808 polypeptide, which is (1) fewer than 512, 510,
500, 490, 480, 470, 460, 450, 440, 430, 420, 410, 400, 390, 380,
370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250,
240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120,
110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids
in length; (2) contains at least one, preferably at least 2, 3, 4,
5, 6, 7, 8, 9, or 10 conservative amino acid substitutions in the
sequence of SEQ ID NO: 6; and (3) elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0028] An additional embodiment of the invention provides an
isolated fragment of a CT808 polypeptide, which is (1) fewer than
512, 510, 500, 490, 480, 470, 460, 450, 440, 430, 420, 410, 400,
390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270,
260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140,
130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15
amino acids in length; (2) contains at least one, preferably at
least 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid
substitutions in the sequence of SEQ ID NO: 6 and/or has at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
flanking amino acids) at the N- and/or C-terminus of the sequence
of SEQ ID NO: 6; and (3) elicits at least a 3-, 4-, 5-, 6-, 7-, 8-,
10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0029] In a seventh aspect, the present invention provides an
isolated CT823 polypeptide containing a sequence substantially
identical SEQ ID NO: 7, or fragment thereof, which elicits at least
a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-,
90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0030] An additional aspect of the invention is an isolated
fragment of a CT823 polypeptide, which is fewer than 497, 490, 480,
470, 460, 450, 440, 430, 420, 410, 400, 390, 380, 370, 360, 350,
340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230, 220,
210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80,
70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids in length and
elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-,
60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase in
interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay. Desirable CT823
fragments have at least 7 amino acids and/or elicit a CD8.sup.+ T
cell response.
[0031] A related embodiment of the invention provides an isolated
fragment of a CT823 polypeptide, which is (1) fewer than 497, 490,
480, 470, 460, 450, 440, 430, 420, 410, 400, 390, 380, 370, 360,
350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230,
220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100,
90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids in
length; (2) contains at least one, preferably at least 2, 3, 4, 5,
6, 7, 8, 9, or 10 conservative amino acid substitutions in the
sequence of SEQ ID NO: 7; and (3) elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0032] An additional embodiment of the invention provides an
isolated fragment of a CT823 polypeptide, which is (1) fewer than
497, 490, 480, 470, 460, 450, 440, 430, 420, 410, 400, 390, 380,
370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250,
240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120,
110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids
in length; (2) contains at least one, preferably at least 2, 3, 4,
5, 6, 7, 8, 9, or 10 conservative amino acid substitutions in the
sequence of SEQ ID NO: 7 and/or has at least one flanking amino
acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids)
at the N- and/or C-terminus of the sequence of SEQ ID NO: 7; and
(3) elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-,
50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase in
interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay.
[0033] In an eighth aspect, the present invention provides an
isolated CT062 polypeptide containing a sequence substantially
identical SEQ ID NO: 8, which elicits at least a 3-, 4-, 5-, 6-,
7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0034] A related embodiment of the invention provides a CT062
polypeptide, which (1) contains at least one, preferably at least
2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitutions
in the sequence of SEQ ID NO: 8 and/or has at least one flanking
amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 flanking amino
acids) at the N- and/or C-terminus of the sequence of SEQ ID NO: 8;
and (2) elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-,
40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase in
interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay.
[0035] In an ninth aspect, the present invention provides an
isolated CT062 fragment containing a sequence substantially
identical SEQ ID NO: 9 (i.e., amino acids 23-412 of full-length
CT062), which elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-,
30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase
in interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay.
[0036] An additional aspect of the invention is an isolated
fragment of a CT062 polypeptide, which is fewer than 390, 380, 370,
360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240,
230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110,
100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids in
length and elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-,
30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase
in interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay. Desirable CT062
fragments have at least 7 amino acids and/or elicit a CD8.sup.+ T
cell response.
[0037] A related embodiment of the invention provides an isolated
fragment of a CT062 polypeptide, which is (1) fewer than 390, 380,
370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250,
240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120,
110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or amino acids in
length; (2) contains at least one, preferably at least 2, 3, 4, 5,
6, 7, 8, 9, or 10 conservative amino acid substitutions in the
sequence of SEQ ID NO: 9 and/or has at least one flanking amino
acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids)
at the N- and/or C-terminus of the sequence of SEQ ID NO: 9; and
(3) elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-,
50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase in
interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay.
[0038] In a tenth aspect, the present invention provides an
isolated CT104 polypeptide containing a sequence substantially
identical SEQ ID NO: 10, or fragment thereof, which elicits at
least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-,
80-, 90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0039] An additional aspect of the invention is an isolated
fragment of a CT104 polypeptide, which is fewer than 298, 290, 280,
270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150,
140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or
15 amino acids in length and elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay. Desirable CT104 fragments have at least
7 amino acids and/or elicit a CD8.sup.+ T cell response.
[0040] A related embodiment of the invention provides an isolated
fragment of a CT104 polypeptide, which is (1) fewer than 298, 290,
280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160,
150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25,
20, or 15 amino acids in length; (2) contains at least one,
preferably at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative
amino acid substitutions in the sequence of SEQ ID NO: 10; and (3)
elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-,
60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase in
interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay.
[0041] An additional embodiment of the invention provides an
isolated fragment of a CT104 polypeptide, which is (1) fewer than
298, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180,
170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 35,
30, 25, 20, or 15 amino acids in length; (2) contains at least one,
preferably at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative
amino acid substitutions in the sequence of SEQ ID NO: 10 and/or
has at least one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8,
9, or 10 flanking amino acids) at the N- and/or C-terminus of the
sequence of SEQ ID NO: 10; and (3) elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0042] In an eleventh aspect, the present invention provides an
isolated CT111 polypeptide containing a sequence substantially
identical SEQ ID NO: 11, or fragment thereof, which elicits at
least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-,
80-, 90-, 100-, 200-, or 500-fold increase in interferon-.gamma.
production from a population of T-lymphocytes compared to the level
of interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0043] An additional aspect of the invention is an isolated
fragment of a CT111 polypeptide, which is fewer than 102, 100, 90,
80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids in length and
elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-,
60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase in
interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay. Desirable CT111
fragments have at least 7 amino acids and/or elicit a CD8.sup.+ T
cell response.
[0044] A related embodiment of the invention provides an isolated
fragment of a CT111 polypeptide, which is (1) fewer than 102, 100,
90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids in
length; (2) contains at least one, preferably at least 2, 3, 4, 5,
6, 7, 8, 9, or 10 conservative amino acid substitutions in the
sequence of SEQ ID NO: 11; and (3) elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production elicited from a non-immunogenic
peptide in the same assay.
[0045] An additional embodiment of the invention provides an
isolated fragment of a CT111 polypeptide, which is (1) fewer than
102, 100, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, or 15 amino acids
in length; (2) contains at least one, preferably at least 2, 3, 4,
5, 6, 7, 8, 9, or 10 conservative amino acid substitutions in the
sequence of SEQ ID NO: 11 and/or has at least one flanking amino
acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids)
at the N- and/or C-terminus of the sequence of SEQ ID NO: 11; and
(3) elicits at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-,
50-, 60-, 70-, 80-, 90-, 100-, 200-, or 500-fold increase in
interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production elicited
from a non-immunogenic peptide in the same assay.
[0046] The invention further provides a fusion protein containing
(1) the sequence of any of the above polypeptides or fragments of
the invention, and (2) a fusion partner.
[0047] The invention further provides pharmaceutical compositions
containing one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of
any of the above described polypeptides, fragments, and fusion
proteins of the invention and a pharmaceutically acceptable
carrier.
[0048] The invention additionally provides vaccines containing one
or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of any of the
above described polypeptides, fragments, and fusion proteins of the
invention and a pharmaceutically acceptable carrier. Additionally,
the invention provides DNA vaccines containing a polynucleotide
sequence that encodes one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10) of any of the above described polypeptides, fragments, and
fusion proteins of the invention and a pharmaceutically acceptable
carrier.
[0049] In preferred embodiments of all the above aspects, the
polypeptides, polypeptide fragments, fusion proteins, and vaccines
of the invention (e.g., protein and DNA vaccines) elicit an immune
response when administered to a mammal. Desirably, the
polypeptides, polypeptide fragments, fusion proteins, and vaccines
of the invention elicit an immune response when administered to a
human.
[0050] The invention further provides a method of treating or
preventing a bacterial infection, preferably a Chlamydia infection,
by administering to a subject in need thereof (e.g., a subject who
has or is at risk for contracting Chlamydia), a therapeutically
effective amount of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10) of any of the above described polypeptides, fragments,
fusion proteins, vaccines (e.g., protein vaccines or DNA vaccines)
of the present invention. In a desirable embodiments of the method
of the invention, the polypeptide, fragment, fusion protein, or
vaccine (e.g., protein vaccines or DNA vaccines) of the present
invention is capable of reducing (e.g., at least a 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, or even 100% reduction) one or more
symptoms of C. trachomatis infection in a patient (e.g., cystitis,
pain during urination, pain or bleeding during or after sexual
intercourse, abdominal pains, irregular menstral bleeding, painful
swelling and irritation of the eyes, white/cloudy and watery penile
discharge, fever, lower back pain, and swollen or painful
testicles) or reducing the likelihood (e.g., at least a 5%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or even 100% reduction) of
becoming infected with C. trachomatis.
[0051] In desirable embodiments of the method, the polypeptide,
fragment, fusion protein, or vaccine (e.g., protein vaccines or DNA
vaccines) of the present invention is capable of generating an
immune response in a subject and/or is administered in a
pharmaceutically acceptable carrier.
DEFINITIONS
[0052] By a "CT491 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO: 1.
Desirably, a CT491 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% sequence identity to the amino acid sequence of
SEQ ID NO: 1. Desirably, a CT491 polypeptide elicits at least a 3-,
4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-,
100-, 200-, or 500-fold increase in interferon-.gamma. production
from a population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0053] By a "fragment of a CT491 polypeptide" or a "CT491 fragment"
is meant a fragment of a CT491 polypeptide that contains fewer than
464 amino acids. Desirably, a CT491 fragment elicits at least a 3-,
4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-,
100-, 200-, or 500-fold increase in interferon-.gamma. production
from a population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment contains fewer than 464, 460, 450,
440, 430, 420, 410, 400, 390, 380, 370, 360, 350, 340, 330, 320,
310, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190,
180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50,
40, 35, 30, 25, 20, 15, or 10 amino acids, and desirably, is
immunogenic. Preferred CT491 fragments are between 7 and 463 amino
acids in length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 40, 50, 100, or 150 amino acids in length). A CT491
fragment may contain one or more conservative amino acid
substitutions in the sequence of SEQ ID NO: 1. Additional desirable
CT491 fragments contain one or more conservative amino acid
substitutions in the sequence of SEQ ID NO: 1 and/or have at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, or 15 flanking amino acids) at the N- and/or C-terminus
of the sequence of SEQ ID NO: 1. Other preferred CT491 fragments
contain seven or more continuous amino acids of the sequence of SEQ
ID NO: 1.
[0054] Non-limiting examples of a CT491 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, 120-160, 130-170, 140-180,
150-190, 160-200, 170-210, 180-220, 190-230, 200-240, 210-250,
220-260, 230-270, 240-280, 250-290, 260-300, 270-310, 280-320,
290-330, 300-340, 310-350, 320-360, 330-370, 340-380, 350-390,
360-400, 370-410, 380-420, 390-430, 400-440, 410-450, 420-460, and
424-464 of the sequence of SEQ ID NO: 1; and these fragments having
one or more of the following features: one or more conservative
amino acid substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, or 16 conservative amino acid substitutions) in the
sequence of SEQ ID NO: 1; one or more amino acids (e.g., 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids)
truncated from the N and/or C-terminus of the sequence of SEQ ID
NO: 1; and at least one flanking amino acid (e.g., 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 flanking amino acids) at the
N- and/or C-terminus of the sequence of SEQ ID NO: 1.
[0055] By a "CT601 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO: 2.
Desirably, a CT601 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% sequence identity to the amino acid sequence of
SEQ ID NO: 2. Desirably, a CT601 polypeptide elicits at least a 3-,
4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-,
100-, 200-, or 500-fold increase in interferon-.gamma. production
from a population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0056] By a "fragment of a CT601 polypeptide" or "CT601 fragment"
is meant a fragment of a CT601 polypeptide containing fewer than
200 amino acids. Desirably, a CT601 fragment elicits at least a 3-,
4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-,
100-, 200-, or 500-fold increase in interferon-.gamma. production
from a population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment is fewer than 200, 190, 180, 170,
160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 25,
20, 15, or 10 amino acids in length, and desirably, is immunogenic.
Preferred CT601 fragments are between 7 and 199 amino acids in
length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
40, 50, 100, or 150 amino acids in length). A CT601 fragment may
contain one or more conservative amino acid substitutions in the
sequence of SEQ ID NO: 2. Additional desirable CT601 fragments
contain one or more conservative amino acid substitutions in the
sequence of SEQ ID NO: 2 and/or at least one flanking amino acid
(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids) at
the N- and/or C-terminus of the sequence of SEQ ID NO: 2. Other
preferred CT601 fragments contain seven or more continuous amino
acids of the sequence of SEQ ID NO: 2.
[0057] Non-limiting examples of a CT601 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, 120-160, 130-170, 140-180,
150-190, and 160-200 of the sequence of SEQ ID NO: 2; and these
fragments having one or more of the following features: one or more
conservative amino acid substitutions (e.g., 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, or 16 conservative amino acid
substitutions) in the sequence of SEQ ID NO: 2; one or more amino
acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or
16 amino acids) truncated from the N and/or C-terminus of the
sequence of SEQ ID NO: 2; and at least one flanking amino acid
(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids) at
the N- and/or C-terminus of the sequence of SEQ ID NO: 2.
[0058] By a "CT687 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO: 3.
Desirably, a CT687 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% identity to the amino acid sequence of SEQ ID NO:
3. Desirably, a CT687 polypeptide elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0059] By "fragment of a CT687 polypeptide" or a "CT687 fragment"
is meant a fragment of a CT687 polypeptide containing fewer than
401 amino acids. Preferred CT687 fragments are between 7 and 400
amino acids in length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 40, 50, 100, or 150 amino acids in length).
Desirably, a CT687 fragment elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment is fewer than 401, 400, 390, 380,
370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250,
240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120,
110, 100, 90, 80, 70, 60, 50, 40, 30, 25, 20, 15, or 10 amino
acids, and desirably, is immunogenic. A CT687 fragment may contain
one or more conservative amino acid substitutions in the sequence
of SEQ ID NO: 3. Additional desirable CT687 fragments contain one
or more conservative amino acid substitutions in the sequence of
SEQ ID NO: 3 and/or at least one flanking amino acid (e.g., 1, 2,
3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids) at the N- and/or
C-terminus of the sequence of SEQ ID NO: 3. Other preferred CT687
fragments contain seven or more continuous amino acids of the
sequence of SEQ ID NO: 3.
[0060] Non-limiting examples of a CT687 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, 120-160, 130-170, 140-180,
150-190, 160-200, 170-210, 180-220, 190-230, 200-240, 210-250,
220-260, 230-270, 240-280, 250-290, 260-300, 270-310, 280-320,
290-330, 300-340, 310-350, 320-360, 330-370, 340-380, 350-390, and
360-401 of the sequence of SEQ ID NO: 3; and these fragments having
one or more of the following features: one or more conservative
amino acid substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, or 16 conservative amino acid substitutions) in the
sequence of SEQ ID NO: 3; one or more amino acids (e.g., 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids)
truncated from the N- and/or C-terminus of the sequence of SEQ ID
NO: 3; and at least one flanking amino acid (e.g., 1, 2, 3, 4, 5,
6, 7, 8, 9, or 10 flanking amino acids) at the N- and/or C-terminus
of the sequence of SEQ ID NO: 3.
[0061] By a "CT732 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO: 4.
Desirably, a CT732 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% identity to the amino acid sequence of SEQ ID NO:
4. Desirably, a CT732 polypeptide elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0062] By "fragment of a CT732 polypeptide" or a "CT732 fragment"
is meant a fragment of a CT732 polypeptide containing fewer than
157 amino acids. Preferred CT732 fragments are between 7 and 156
amino acids in length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 40, 50, 100, or 150 amino acids in length).
Desirably, a CT732 fragment elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment is fewer than 157, 150, 140, 130,
120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 25, 20, 15, or amino
acids, and desirably, is immunogenic. A CT732 fragment may contain
one or more conservative amino acid substitutions in the sequence
of SEQ ID NO: 4. Additional desirable CT732 fragments contain one
or more conservative amino acid substitutions in the sequence of
SEQ ID NO: 4 and/or at least one flanking amino acid (e.g., 1, 2,
3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids) at the N- and/or
C-terminus of the sequence of SEQ ID NO: 4. Other preferred CT732
fragments contain seven or more continuous amino acids of the
sequence of SEQ ID NO: 4.
[0063] Non-limiting examples of a CT732 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, and 120-157 of the sequence of
SEQ ID NO: 4; and these fragments having one or more of the
following features: one or more conservative amino acid
substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, or 16 conservative amino acid substitutions) in the sequence of
SEQ ID NO: 4; one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids) truncated from the
N and/or C-terminus of the sequence of SEQ ID NO: 4; and at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or
flanking amino acids) at the N- and/or C-terminus of the sequence
of SEQ ID NO: 4.
[0064] By a "CT781 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO: 5.
Desirably, a CT781 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% identity to the amino acid sequence of SEQ ID NO:
5. Desirably, a CT781 polypeptide elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0065] By "fragment of a CT781 polypeptide" or a "CT781 fragment"
is meant a fragment of a CT781 polypeptide containing fewer than
526 amino acids. Preferred CT781 fragments are between 7 and 525
amino acids in length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 40, 50, 100, or 150 amino acids in length).
Desirably, a CT781 fragment elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment is fewer than 526, 510, 500, 490,
480, 470, 460, 450, 440, 430, 420, 410, 400, 390, 380, 370, 360,
350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230,
220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100,
90, 80, 70, 60, 50, 40, 30, 25, 20, 15, or 10 amino acids, and
desirably, is immunogenic. A CT781 fragment may contain one or more
conservative amino acid substitutions in the sequence of SEQ ID NO:
5. Additional desirable CT781 fragments contain one or more
conservative amino acid substitutions in the sequence of SEQ ID NO:
5 and/or at least one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6,
7, 8, 9, or 10 flanking amino acids) at the N- and/or C-terminus of
the sequence of SEQ ID NO: 5. Other preferred CT781 fragments
contain seven or more continuous amino acids of the sequence of SEQ
ID NO: 5.
[0066] Non-limiting examples of a CT781 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, 120-160, 130-170, 140-180,
150-190, 160-200, 170-210, 180-220, 190-230, 200-240, 210-250,
220-260, 230-270, 240-280, 250-290, 260-300, 270-310, 280-320,
290-330, 300-340, 310-350, 320-360, 330-370, 340-380, 350-390,
360-400, 370-410, 380-420, 390-430, 400-440, 410-450, 420-460,
430-470, 440-480, 450-490, 460-500, 470-510, 480-520, and 485-526
of the sequence of SEQ ID NO: 5; and these fragments having one or
more of the following features: one or more conservative amino acid
substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, or 16 conservative amino acid substitutions) in the sequence of
SEQ ID NO: 5; one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids) truncated from the
N and/or C-terminus of the sequence of SEQ ID NO: 5; and at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
flanking amino acids) at the N- and/or C-terminus of the sequence
of SEQ ID NO: 5.
[0067] By a "CT808 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO: 6.
Desirably, a CT808 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% identity to the amino acid sequence of SEQ ID NO:
6. Desirably, a CT808 polypeptide elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0068] By "fragment of a CT808 polypeptide" or a "CT808 fragment"
is meant a fragment of a CT808 polypeptide containing fewer than
512 amino acids. Preferred CT808 fragments are between 7 and 511
amino acids in length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 40, 50, 100, or 150 amino acids in length).
Desirably, a CT808 fragment elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment is fewer than 512, 510, 500, 490,
480, 470, 460, 450, 440, 430, 420, 410, 400, 390, 380, 370, 360,
350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230,
220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100,
90, 80, 70, 60, 50, 40, 30, 25, 20, 15, or 10 amino acids, and
desirably, is immunogenic. A CT808 fragment may contain one or more
conservative amino acid substitutions in the sequence of SEQ ID NO:
6. Additional desirable CT808 fragments contain one or more
conservative amino acid substitutions in the sequence of SEQ ID NO:
6 and/or at least one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6,
7, 8, 9, or 10 flanking amino acids) at the N- and/or C-terminus of
the sequence of SEQ ID NO: 6. Other preferred CT808 fragments
contain seven or more continuous amino acids of the sequence of SEQ
ID NO: 6.
[0069] Non-limiting examples of a CT808 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, 120-160, 130-170, 140-180,
150-190, 160-200, 170-210, 180-220, 190-230, 200-240, 210-250,
220-260, 230-270, 240-280, 250-290, 260-300, 270-310, 280-320,
290-330, 300-340, 310-350, 320-360, 330-370, 340-380, 350-390,
360-400, 370-410, 380-420, 390-430, 400-440, 410-450, 420-460,
430-470, 440-480, 450-490, 460-500, and 470-512 of the sequence of
SEQ ID NO: 6; and these fragments having one or more of the
following features: one or more conservative amino acid
substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, or 16 conservative amino acid substitutions) in the sequence of
SEQ ID NO: 6; one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids) truncated from the
N and/or C-terminus of the sequence of SEQ ID NO: 6; and at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
flanking amino acids) at the N- and/or C-terminus of the sequence
of SEQ ID NO: 6.
[0070] By a "CT823 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO: 7.
Desirably, a CT823 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% identity to the amino acid sequence of SEQ ID NO:
7. Desirably, a CT823 polypeptide elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0071] By "fragment of a CT823 polypeptide" or a "CT823 fragment"
is meant a fragment of a CT823 polypeptide containing fewer than
497 amino acids. Preferred CT823 fragments are between 7 and 496
amino acids in length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 40, 50, 100, or 150 amino acids in length).
Desirably, a CT823 fragment elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment is fewer than 497, 490, 480, 470,
460, 450, 440, 430, 420, 410, 400, 390, 380, 370, 360, 350, 340,
330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210,
200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70,
60, 50, 40, 30, 25, 20, 15, or 10 amino acids, and desirably, is
immunogenic. A CT823 fragment may contain one or more conservative
amino acid substitutions in the sequence of SEQ ID NO: 7.
Additional desirable CT823 fragments contain one or more
conservative amino acid substitutions in the sequence of SEQ ID NO:
7 and/or at least one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6,
7, 8, 9, or 10 flanking amino acids) at the N- and/or C-terminus of
the sequence of SEQ ID NO: 7. Other preferred CT823 fragments
contain seven or more continuous amino acids of the sequence of SEQ
ID NO: 7.
[0072] Non-limiting examples of a CT823 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, 120-160, 130-170, 140-180,
150-190, 160-200, 170-210, 180-220, 190-230, 200-240, 210-250,
220-260, 230-270, 240-280, 250-290, 260-300, 270-310, 280-320,
290-330, 300-340, 310-350, 320-360, 330-370, 340-380, 350-390,
360-400, 370-410, 380-420, 390-430, 400-440, 410-450, 420-460,
430-470, 440-480, 450-490, and 456-497 of the sequence of SEQ ID
NO: 7; and these fragments having one or more of the following
features: one ore more conservative amino acid substitutions (e.g.,
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16
conservative amino acid substitutions) in the sequence of SEQ ID
NO: 7; one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, or 16 amino acids) truncated from the N
and/or C-terminus of the sequence of SEQ ID NO: 7; and at least one
flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
flanking amino acids) at the N- and/or C-terminus of the sequence
of SEQ ID NO: 7.
[0073] By a "CT062 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO: 8.
Desirably, a CT062 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% identity to the amino acid sequence of SEQ ID NO:
8. Desirably, a CT062 polypeptide elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0074] By "fragment of a CT062 polypeptide" or a "CT062 fragment"
is meant a polypeptide that is substantially identical to the
sequence of SEQ ID NO: 9 (amino acids 23-412 of whole length CT062,
SEQ ID NO: 8) containing fewer than 390 amino acids. Preferred
CT062 fragments are between 7 and 389 amino acids in length (e.g.,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 40, 50, 100,
or 150 amino acids in length). Desirably, a CT062 fragment elicits
at least a 3-, 4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-,
70-, 80-, 90-, 100-, 200-, or 500-fold increase in
interferon-.gamma. production from a population of T-lymphocytes
compared to the level of interferon-.gamma. production from
T-lymphocytes treated with a non-antigenic peptide in the same
assay (e.g., a peptide which elicits the lowest measurable value of
IFN-.gamma. in the same assay). Desirably, the fragment is fewer
than 390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280,
270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150,
140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 25, 20, 15, or
10 amino acids, and desirably, is immunogenic. A CT062 fragment may
contain one or more conservative amino acid substitutions in the
sequence of SEQ ID NO: 9. Additional desirable CT062 fragments
contain one or more conservative amino acid substitutions in the
sequence of SEQ ID NO: 9 and/or at least one flanking amino acid
(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids) at
the N- and/or C-terminus of the sequence of SEQ ID NO: 9. Other
preferred CT062 fragments contain seven or more continuous amino
acids of the sequence of SEQ ID NO: 9.
[0075] Non-limiting examples of a CT062 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, 120-160, 130-170, 140-180,
150-190, 160-200, 170-210, 180-220, 190-230, 200-240, 210-250,
220-260, 230-270, 240-280, 250-290, 260-300, 270-310, 280-320,
290-330, 300-340, 310-350, 320-360, 330-370, 340-380, and 350-390
of the sequence of SEQ ID NO: 9; and these fragments having one or
more of the following features: one or more conservative amino acid
substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, or 16 conservative amino acid substitutions) in the sequence of
SEQ ID NO: 9; one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids) truncated from the
N and/or C-terminus of the sequence of SEQ ID NO: 9; and at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
flanking amino acids) in the sequence of SEQ ID NO: 9.
[0076] By a "CT104 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO:
10. Desirably, a CT104 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% identity to the amino acid sequence of SEQ ID NO:
10. Desirably, a CT104 polypeptide elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0077] By "fragment of a CT104 polypeptide" or a "CT104 fragment"
is meant a fragment of a CT104 polypeptide containing fewer than
298 amino acids. Preferred CT823 fragments are between 7 and 297
amino acids in length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 40, 50, 100, or 150 amino acids in length).
Desirably, a CT104 fragment elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment is fewer than 298, 290, 280, 270,
260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140,
130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 25, 20, 15, or 10
amino acids, and desirably, is immunogenic. A CT104 fragment may
contain one or more conservative amino acid substitutions in the
sequence of SEQ ID NO: 10. Additional desirable CT104 fragments
contain one or more conservative amino acid substitutions in the
sequence of SEQ ID NO: 10 and/or at least one flanking amino acid
(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 flanking amino acids) at
the N- and/or C-terminus of the sequence of SEQ ID NO: 10. Other
preferred CT104 fragments contain seven or more continuous amino
acids of the sequence of SEQ ID NO: 10.
[0078] Non-limiting examples of a CT104 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, 70-110,
80-120, 90-130, 100-140, 110-150, 120-160, 130-170, 140-180,
150-190, 160-200, 170-210, 180-220, 190-230, 200-240, 210-250,
220-260, 230-270, 240-280, 250-290, and 258-298 of the sequence of
SEQ ID NO: 10; and these fragments having one or more of the
following features: one or more conservative amino acid
substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, or 16 conservative amino acid substitutions) in the sequence of
SEQ ID NO: 10; one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids) truncated from the
N and/or C-terminus of the sequence of SEQ ID NO: 10; and at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
flanking amino acids) at the N- and/or C-terminus of the sequence
of SEQ ID NO: 10.
[0079] By a "CT111 polypeptide" is meant a polypeptide that is
substantially identical to the amino acid sequence of SEQ ID NO:
11. Desirably, a CT111 polypeptide has at least 80%, 85%, 90%, 95%,
99%, or even 100% identity to the amino acid sequence of SEQ ID NO:
11. Desirably, a CT111 polypeptide elicits at least a 3-, 4-, 5-,
6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-,
200-, or 500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay).
[0080] By "fragment of a CT111 polypeptide" or a "CT111 fragment"
is meant a fragment of a CT111 polypeptide containing fewer than
102 amino acids. Preferred CT111 fragments are between 7 and 101
amino acids in length (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 40, 50, 100, or 150 amino acids in length).
Desirably, a CT111 fragment elicits at least a 3-, 4-, 5-, 6-, 7-,
8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Desirably, the fragment is fewer than 102, 100, 90, 80, 70,
60, 50, 40, 30, 25, 20, 15, or 10 amino acids, and desirably, is
immunogenic. A CT111 fragment may contain one or more conservative
amino acid substitutions in the sequence of SEQ ID NO: 11.
Additional desirable CT111 fragments contain one or more
conservative amino acid substitutions in the sequence of SEQ ID NO:
11 and/or at least one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6,
7, 8, 9, or 10 flanking amino acids) at the N- and/or C-terminus of
the sequence of SEQ ID NO: 11. Other preferred CT111 fragments
contain seven or more continuous amino acids of the sequence of SEQ
ID NO: 11.
[0081] Non-limiting examples of a CT111 fragment include amino
acids 1-40, 10-50, 20-60, 30-70, 40-80, 50-90, 60-100, and 60-102
of the sequence of SEQ ID NO: 11; and these fragments having one or
more of the following features: one or more conservative amino acid
substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, or 16 conservative amino acid substitutions) in the sequence of
SEQ ID NO: 11; one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids) truncated from the
N and/or C-terminus of the sequence of SEQ ID NO: 11; and at least
one flanking amino acid (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
flanking amino acids) at the N- and/or C-terminus of the sequence
of SEQ ID NO: 11.
[0082] By "substantially identical" is meant a polypeptide
exhibiting at least 50%, desirably 60%, 70%, 75%, or 80%, more
desirably 85%, 90%, or 95%, and most desirably 99% amino acid
sequence identity to a reference amino acid sequence. The length of
comparison sequences will generally be at least 10 amino acids,
desirably at least 15 contiguous amino acids, more desirably at
least 20, 25, 50, 75, 90, 100, 150, 200, 250, 300, or 350
contiguous amino acids, and most desirably the full-length amino
acid sequence.
[0083] Sequence identity may be measured using sequence analysis
software on the default setting (e.g., Sequence Analysis Software
Package of the Genetics Computer Group, University of Wisconsin
Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705).
Such software may match similar sequences by assigning degrees of
homology to various substitutions, deletions, and other
modifications.
[0084] Multiple sequences may also be aligned using the Clustal
W(1.4) program (produced by Julie D. Thompson and Toby Gibson of
the European Molecular Biology Laboratory, Germany and Desmond
Higgins of European Bioinformatics Institute, Cambridge, UK) by
setting the pairwise alignment mode to "slow," the pairwise
alignment parameters to include an open gap penalty of 10.0 and an
extend gap penalty of 0.1, as well as setting the similarity matrix
to "blosum." In addition, the multiple alignment parameters may
include an open gap penalty of 10.0, an extend gap penalty of 0.1,
as well as setting the similarity matrix to "blosum," the delay
divergent to 40%, and the gap distance to 8.
[0085] By "conservative amino acid substitution," as used herein,
is meant replacement, in an amino acid sequence, of an amino acid
for another within a family of amino acids that are related in the
chemical nature of their side chains.
[0086] Genetically encoded amino acids can be divided into four
families: acidic (aspartate, glutamate); basic (lysine, arginine,
histidine); nonpolar (alanine, valine, leucine, isoleucine,
proline, phenylalanine, methionine, tryptophan); and uncharged
polar (glycine, asparagine, glutamine, cysteine, serine, threonine,
tyrosine). Phenylalanine, tryptophan, and tyrosine are sometimes
grouped as aromatic amino acids. In similar fashion, the amino
acids can also be separated into the following groups: acidic
(aspartate, glutamate); basic (lysine, arginine, histidine);
alipathic (glycine, alanine, valine, leucine, isoleucine, serine,
threonine), with serine and threonine optionally grouped separately
as alipathic-hydroxyl; aromatic (phenylalanine, tyrosine,
tryptophan); amide (asparagine, glutamine); and sulfur-containing
(cysteine, methionine).
[0087] Whether a change in the amino acid sequence results in a
functional homolog can be determined by assessing the ability of
the variant peptide to function in a fashion similar to the
wild-type protein using standard methods such as the assays
described herein. For example, C. trachomatis-specific CD4.sup.+ or
CD8.sup.+ cells may be used to determine whether specific C.
trachomatis polypeptides or fragments thereof, are immunogenic.
Desirable embodiments of the invention, include at least one
conservative amino acid substitution in the amino acid sequence of
SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11; and more desirably
1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid
substitutions in the sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, or 11.
[0088] By "flanking amino acid" is meant an amino acid in a
polypeptide sequence that is immediately adjacent to the N- or
C-terminus of a particular defined sequence. Desirably, a flanking
amino acid is present on the N- and/or C-terminus of the amino acid
sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, or a
fragment thereof; and more desirably, 1, 2, 3, 4, 5, 6, 7, 8, 9, or
flanking amino acids are present at the N- and/or C-terminus of the
amino acid sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or
11, or fragment thereof.
[0089] As used herein "fusion protein" refers to a polypeptide
consisting of (1) a CT491 polypeptide, CT491 fragment, CT601
polypeptide, CT601 fragment, CT781 polypeptide, CT781 fragment,
CT687 polypeptide, CT687 fragment, CT732 polypeptide, CT732
fragment, CT808 polypeptide, CT808 fragment, CT823 polypeptide,
CT823 fragment, CT062 polypeptide, CT062 fragment, CT104
polypeptide, CT104 fragment, CT111 polypeptide, or CT111 fragment
of the present invention; and (2) a fusion partner.
[0090] As used herein "fusion partner" refers to a heterologous
sequence that can be fused to a CT491 polypeptide, CT491 fragment,
CT601 polypeptide, CT601 fragment, CT781 polypeptide, CT781
fragment, CT687 polypeptide, CT687 fragment, CT732 polypeptide,
CT732 fragment, CT808 polypeptide, CT808 fragment, CT823
polypeptide, CT823 fragment, CT062 polypeptide, CT062 fragment,
CT104 polypeptide, CT104 fragment, CT111 polypeptide, or CT111
fragment of the present invention. Desirably, the fusion partner
provides a new function or activity to the CT491 polypeptide, CT491
fragment, CT601 polypeptide, CT601 fragment, CT781 polypeptide,
CT781 fragment, CT687 polypeptide, CT687 fragment, CT732
polypeptide, CT732 fragment, CT808 polypeptide, CT808 fragment,
CT823 polypeptide, CT823 fragment, CT062 polypeptide, CT062
fragment, CT104 polypeptide, CT104 fragment, CT111 polypeptide, or
CT111 fragment. Examples of fusion partners are described herein
and include detection markers, DNA binding domains, gene activation
domains, stabilizing domains, or sequences which aid in production
or purification of the protein.
[0091] As used herein "immune response" refers to the activation of
an organism's immune system in response to an antigen or infectious
agent. In vertebrates, this may include, but is not limited to, one
or more of the following: naive B cell maturation into memory B
cells; antibody production by plasma cells (effector B cells);
induction of cell-mediated immunity; activation and cytokine
release by CD4.sup.+ T cells; activation and cytokine release of
CD8.sup.+ T cells; cytokine recruitment and activation of
phagocytic cells (e.g., macrophages, neutrophils, eosinophils);
and/or complement activation.
[0092] By "immunogenic" is meant any substance that is capable of
inducing an immune response in a subject.
[0093] By "non-antigenic" is meant any peptide which elicits the
lowest level of interferon-.gamma. production compared to other
tested peptides in the T-lymphocyte assays described in the
Examples. For example, a non-antigenic peptide elicits a level of
interferon-.gamma. production that is at least 4-fold lower (e.g.,
5-fold, 6-fold, 7-fold, or 8-fold lower) than the level of
interferon-.gamma. production that is elicited using an antigenic
peptide. The non-antigenic peptide may be a human peptide, a
Chlamydia trachomatis peptide, or a peptide from any other
microorganism. Non-limiting examples of non-antigenic peptides
include Listeria monocytogenes listeriolysin 0 (LLO), amino acids
91-99 (GYKDGNEYI; SEQ ID NO: 12); ovalbumin (OVA), amino acids
257-264 (SIINFEKL; SEQ ID NO: 13); and lymphocytic choriomeningitis
virus (LCMV) nucleoprotein (NP), amino acids 118-126 (RPQASGVYM;
SEQ ID NO: 14).
[0094] By "pharmaceutically acceptable salt" is meant any non-toxic
acid addition salt or metal complex used in the pharmaceutical
industry. Examples of acid addition salts include organic acids
such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic,
succinic, benzoic, palmitic, suberic, salicylic, tartaric,
methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the
like; polymeric acids such as tannic acid, carboxymethyl cellulose,
or the like; and inorganic acids such as hydrochloric acid,
hydrobromic acid, sulfuric acid, phosphoric acid, or the like.
Metal complexes include zinc, iron, and the like.
[0095] By "pharmaceutically acceptable carrier" is meant any
solution used to solubilize and deliver an agent to a subject. A
desirable pharmaceutically acceptable carrier is saline. In
desirable embodiments, a pharmaceutically acceptable carrier
includes an adjuvant. Exemplary adjuvants are described herein.
Other physiologically acceptable carriers and their formulations
are known to one skilled in the art and described, for example, in
Remington's Pharmaceutical Sciences, (20th edition), ed. A.
Gennaro, 2003, Lippincott Williams & Wilkins.
[0096] By "isolated" is meant a protein (or a fragment thereof)
that has been separated from components that naturally accompany
it. Typically, the polypeptide is substantially isolated when it is
at least 60%, by weight, free from the proteins and naturally
occurring organic molecules with which it is naturally associated.
The definition also extends to a polypeptide separated from its
flanking amino acids (e.g., for an amino acid sequence, isolated
refers to a sequence that is free from the flanking amino acids
with which the sequence is naturally associated in a polypeptide).
Preferably, the polypeptide is at least 75%, more preferably at
least 90%, and most preferably at least 99%, by weight, isolated.
An isolated polypeptide may be obtained by standard techniques, for
example, by extraction from a natural source (e.g., purification
from a cell infected with C. trachomatis), by expression of a
recombinant nucleic acid encoding a CT491 polypeptide, CT491
fragment, CT601 polypeptide, CT601 fragment, CT781 polypeptide,
CT781 fragment, CT687 polypeptide, CT687 fragment, CT732
polypeptide, CT732 fragment, CT808 polypeptide, CT808 fragment,
CT823 polypeptide, CT823 fragment, CT062 polypeptide, CT062
fragment, CT104 polypeptide, CT104 fragment, CT111 polypeptide, or
CT111 fragment; or fusion protein thereof, by chemically
synthesizing the polypeptide. Purity can be measured by any
appropriate method, e.g., by column chromatography, polyacrylamide
gel electrophoresis, or HPLC analysis.
[0097] By a "therapeutically effective amount" is meant the amount
of a immunogenic compound (e.g., polypeptide, fragment, fusion
protein, or vaccine) required to generate in a subject one or more
of the following effects: an immune response; a decrease in the
level of Chlamydia infection (e.g., a reduction of at least 5%,
10%, 20%, or 30%; more desirably 40%, 50%, 60%, or 70%; and most
desirably 80% or 90%); a decrease (e.g., at least a 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, or even 100% reduction) in one or
more symptoms of C. trachomatis infection in a patient (e.g.,
cystitis, pain during urination, pain or bleeding during or after
sexual intercourse, abdominal pains, irregular menstral bleeding,
painful swelling and irritation of the eyes, white/cloudy and
watery penile discharge, fever, lower back pain, and swollen or
painful testicles); or increased resistance to a new Chlamydia
infection (e.g., an increase of at least 5%, 10%, 20%, 30%, 40%, or
50%; more desirably 60%, 70%, 80%, or 90%; or most desirably 100%,
200%, or 300%).
BRIEF DESCRIPTION OF THE DRAWINGS
[0098] FIG. 1 is the complete amino acid sequence of the
polypeptide CT491 (SEQ ID NO: 1) (Genbank Accession number
NP.sub.--220005).
[0099] FIG. 2 is the complete amino acid sequence of the
polypeptide CT601 (SEQ ID NO: 2) (Genbank Accession number
NP.sub.--220117).
[0100] FIG. 3 is the complete amino acid sequence of the
polypeptide CT687 (SEQ ID NO: 3) (Genbank Accession number
NP.sub.--220206).
[0101] FIG. 4 is the complete amino acid sequence of the
polypeptide CT732 (SEQ ID NO: 4) (Genbank Accession number
NP.sub.--220251).
[0102] FIG. 5 is the complete amino acid sequence of the
polypeptide CT781 (SEQ ID NO: 5) (Genbank Accession number
NP.sub.--220300).
[0103] FIG. 6 is the complete amino acid sequence of the
polypeptide CT808 (SEQ ID NO: 6) (Genbank Accession number
NP.sub.--220328).
[0104] FIG. 7 is the complete amino acid sequence of the
polypeptide CT823 (SEQ ID NO: 7) (Genbank Accession number
NP.sub.--220344).
[0105] FIG. 8 is the full length amino acid sequence of the
polypeptide CT062 (SEQ ID NO: 8) (Genebank Accession number
NP.sub.--219565).
[0106] FIG. 9 is the partial amino acid sequence of the polypeptide
CT062 (SEQ ID NO: 9) (amino acids 23-412 of Genbank Accession
number NP 219565).
[0107] FIG. 10 is the full length amino acid sequence of the
polypeptide CT104 (SEQ ID NO: 10) (Genbank Accession number
NP.sub.--219607).
[0108] FIG. 11 is the full length amino acid sequence of the
polypeptide CT111 (SEQ ID NO: 11) (Genbank Accession number
NP.sub.--219614).
DETAILED DESCRIPTION
[0109] Previous attempts to develop a Chlamydial vaccine have met
with little success (Cotter et al., Infect. Immun. 63:4704-4714,
1995) (Pal et al., Vaccine 17:459-465, 1999) (Pal et al., Infect.
Immun. 65:3361-3369, 1997) (Su et al., Vaccine 13:1023-1032, 1995)
(Taylor et al., Invest. Ophthalmol. Vis. Sci. 29:1847-1853, 1988)
(Zhang et al., J. Infect. Dis. 176:1035-1040, 1997). Subunit
vaccines have the potential to be able to control many important
human pathogens which have thus far resisted classical vaccination
strategies.
[0110] Chlamydia trachomatis is a human pathogen against which a
protective vaccine has not been developed even though it is a
significant burden on human society. It is the most common
bacterial cause of sexually transmitted disease in the United
States. Chronic inflammation in the female genital tract caused by
C. trachomatis can lead to serious pathologies such as pelvic
inflammatory disease and ectopic pregnancy. C. trachomatis is also
the most common cause of preventable blindness worldwide with an
estimated 1-1.5 million people currently blind from the
disease.
[0111] Use of classical vaccinology methods did not yield a
successful vaccine against C. trachomatis pathogen because
immunization with killed bacteria leads to an increase in the
severity of the pathologies associated with the disease and the
lack of a genetic system to manipulate the bacterium has prevented
the development of attenuated Chlamydia strains. A subunit vaccine
in which specific proteins from C. trachomatis are used to elicit
an immune response has the potential to overcome the barriers to a
successful vaccine by eliciting responses to protective antigens
while avoiding the pathological responses associated with
immunization with the entire organism. To make a successful C.
trachomatis subunit vaccine, the proteins in the C. trachomatis
proteome that elicit protective immune responses must be
identified. We report here the identification of new C. trachomatis
proteins that elicit CD8.sup.+ T-cell responses during C.
trachomatis infection.
[0112] The immunogenic Chlamydia peptides of the present invention
were identified in an assay utilizing C. trachomatis-specific
CD8.sup.+ T cells, and an expression library of genomic sequences
from C. trachomatis serovar D. A detailed description of the assay
and its components is provided below.
[0113] The invention features CT491, CT601, CT687, CT732, CT781,
CT808, CT823, CT062, CT104, and CT111 polypeptides, polypeptide
fragments, and fusion proteins. The invention further features
compositions, vaccines (e.g., DNA vaccines), and kits containing
one or more CT491, CT601, CT687, CT732, CT781, CT808, CT823, CT062,
CT104, or CT111 polypeptide, polypeptide fragment, or fusion
protein (or a polynucleotide sequence encoding a polypeptide,
polypeptide fragment, or fusion protein of the present
invention).
[0114] Methods for the addition of flanking amino acids to the
amino or carboxy ends of a specific protein sequence are well known
in the art. The flanking amino acids added may be the naturally
adjoining sequences present in the full-length sequence of the
naturally-occurring polypeptide (e.g., for a CT491 fragment, the
adjoining sequence in the sequence of SEQ ID NO: 1; for a CT601
fragment, the adjoining sequence in the sequence of SEQ ID NO: 2;
for a CT687 fragment, the adjoining sequence in the sequence of SEQ
ID NO: 3; for a CT732 fragment, the adjoining sequence in the
sequence of SEQ ID NO: 4; for a CT781 fragment, the adjoining
sequence in the sequence of SEQ ID NO: 5; for a CT808 fragment, the
adjoining sequence in the sequence of SEQ ID NO: 6; for a CT823
fragment, the adjoining sequence in the sequence of SEQ ID NO: 7;
for a CT062 fragment, the adjoining sequence in the sequence of SEQ
ID NO: 8; for a CT104 fragment, the adjoining sequence in the
sequence of SEQ ID NO: 10; for a CT111 fragment, the adjoining
sequence in the sequence of SEQ ID NO: 11), or may comprise any
other amino acid sequence.
[0115] In addition, the invention also provides fusion proteins
consisting of (1) any of the CT491, CT601, CT687, CT732, CT781,
CT808, CT823, CT062, CT104, or CT111 polypeptides or polypeptide
fragments, and (2) a fusion partner. A fusion partner is a
heterologous protein sequence that may provide an additional
function or activity to the fragment of the invention. For example,
a fusion partner may be detected directly or indirectly (e.g.,
green fluorescent protein (GFP), hemagglutinin, or alkaline
phosphatase), provide a DNA binding domain (e.g., GAL4 or LexA),
provide a gene activation domain (e.g., GAL4 or VP16), stabilize
the polypeptide, or facilitate its production or purification
(e.g., His.sub.6, a myc tag, streptavidin, a SIINFEKL epitope (SEQ
ID NO: 12), or a secretion signal).
[0116] The fusion partner may also contain sequences which provide
immunostimulatory function, examples include interleukin-2 (Fan et
al., Acta Biochim. Biophys. Sin. 38:683-690, 2006), immunoglobulin
(e.g., IgG, IgM, IgE, or IgA), Toll-like receptor-5 flagellin
(Huleatt et al., Vaccine 8:763-775, 2007), simian immunodeficiency
virus Tat (Chen et al., Vaccine 24:708-715, 2006), or
fibrinogen-albumin-IgG receptor of group C streptococci (Schulze et
al., Vaccine 23:1408-1413, 2005). In addition, fusion partner
sequences may be added to enhance solubility or increase half-life,
for example, hydrophilic amino acid residues (Murby et al., Eur. J.
Biochem. 230:38-44, 1995), glycosylation sequences (Sinclair and
Elliott, J. Pharm. Sci. 94:1626-1635, 2005), or the carboxy
terminus of human chorionic gonadotropin or thrombopoeitin (Lee et
al., Biochem. Biophys. Res. Comm. 339:380-385, 2006). Methods for
the addition of these flanking sequences are known in the art and
further described herein.
[0117] In addition, methods for introducing conservative amino acid
substitutions into a polypeptide sequence are also known in the
art. Amino acids within the sequence of SEQ ID NO: 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, or 11 can be replaced with other amino acids having
similar chemical characteristics. For example, a conservative
substitution is replacing one acidic amino acid for another (e.g.,
aspartate for glutamate, or vice versa). Another example, is
replacing one basic amino acid for another (lysine for histidine,
or vice versa).
[0118] Methods for removing amino acids from the amino and/or
carboxy end of a polypeptide sequence are also known in the art.
Amino acids desirably are removed from the amino and/or carboxy end
of a protein fragment of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
or 11.
[0119] The specific polypeptides, polypeptide fragments, or fusion
proteins disclosed herein can be assayed for their immunogenicity
using standard methods as described, for instance, in the Example
below.
CT491, CT601, CT687, CT732, CT781, CT808, CT823, CT062, CT104, and
CT111 Polypeptide, Polypeptide Fragment, or Fusion Protein
Expression
[0120] The CT491, CT601, CT687, CT732, CT781, CT808, CT823, CT062,
CT104, and CT111 polypeptides, polypeptide fragments, or fusion
proteins of the present invention may be produced by transformation
of a suitable host cell with a polynucleotide molecule encoding the
polypepetide, polypeptide fragment, or fusion protein in a suitable
expression vehicle.
[0121] Those skilled in the field of molecular biology will
understand that any of a wide variety of expression systems may be
used to provide the CT491, CT601, CT687, CT732, CT781, CT808,
CT823, CT062, CT104, and CT111 polypeptides, polypeptide fragments,
or fusion proteins disclosed herein. The precise host cell used is
not critical to the invention. CT491, CT601, CT687, CT732, CT781,
CT808, CT823, CT062, CT104, and CT111 polypeptides, polypeptide
fragments, or fusion proteins may be produced in prokaryotic host
(e.g., E. coli) or in a eukaryotic host (e.g., S. cerevisiae,
insect cells, e.g., Sf21 cells, or mammalian cells, e.g., NIH 3T3,
HeLa, or preferably COS cells). Such cells are available from a
wide range of sources (e.g., the American Type Culture Collection,
Manassas, Va.). The method of transformation or transfection and
the choice of expression vehicle will depend on the host system
selected. Transformation and transfection methods are described,
e.g., in Kucherlapati et al. (CRC Crit. Rev. Biochem. 16:349-379,
1982) and in DNA Transfer to Cultured Cells (eds., Ravid and
Freshney, Wiley-Liss, 1998); and expression vehicles may be chosen
from those provided, e.g., in Vectors: Expression Systems Essential
Techniques (ed., Jones, Wiley & Sons Ltd., 1998).
[0122] Once the recombinant polypeptide, polypeptide fragment, or
fusion protein is expressed, it can be isolated, e.g., using
affinity chromatography. In one example, an antibody raised against
a CT491, CT601, CT687, CT732, CT781, CT808, CT823, CT062, CT104, or
CT111 polypeptide, polypeptide fragment, or fusion protein may be
attached to a column and used to isolate the recombinant
polypeptide, polypeptide fragment, or fusion protein. Lysis and
fractionation of polypeptide-, polypeptide fragment-, or fusion
protein-harboring cells prior to affinity chromatography may be
performed by standard methods (see, e.g., Methods in Enzymology,
volume 182, eds., Abelson, Simon, and Deutscher, Elsevier,
1990).
[0123] Once isolated, the recombinant CT491, CT601, CT687, CT732,
CT781, CT808, CT823, CT062, CT104, and CT111 polypeptides,
polypeptide fragments, or fusion proteins can, if desired, be
further purified, e.g., by high performance liquid chromatography
(see e.g., Fisher, Laboratory Techniques in Biochemistry and
Molecular Biology, eds., Work and Burdon, Elsevier, 1980; and
Scopes, Protein Purification: Principles and Practice, Third
Edition, ed., Cantor, Springer, 1994).
[0124] The CT491, CT601, CT687, CT732, CT781, CT808, CT823, CT062,
CT104, and CT111 polypeptides, polypeptide fragments, or fusion
proteins can also be produced by chemical synthesis (e.g., by the
methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984,
The Pierce Chemical Co., Rockford, Ill.; and Solid-Phase Synthesis:
A Practical Guide, ed., Kates and Albericio, Marcel Dekker Inc.,
2000).
[0125] For production of stable cell lines expressing the
polypeptides described herein, PCR-amplified nucleic acids encoding
any of the CT491, CT601, CT687, CT732, CT781, CT808, CT823, CT062,
CT104, or CT111 polypeptides, polypeptide fragments, or fusion
proteins of the present invention may be cloned into the
restriction site of a derivative of a mammalian expression vector.
For example, KA, which is a derivative of pcDNA3 (Invitrogen,
Carlsbad, Calif.) contains a DNA fragment encoding an influenza
virus hemagglutinin (HA). Alternatively, vector derivatives
encoding other tags, such as c-myc or poly-histidine tags, can be
used.
Vaccine Production
[0126] The invention also provides for a vaccine composition
including one or more of the CT491, CT601, CT687, CT732, CT781,
CT808, CT823, CT062, CT104, or CT111 polypeptides, polypeptide
fragments, or fusion proteins of the present invention. The
invention further provides a vaccine composition including one or
more of any of the polypeptides, polypeptide fragments, or fusion
proteins of the present invention combined with one or more
antigens disclosed in U.S. Patent Application Nos. 60/775,462;
60/817,471; and 60/963,215; herein incorporated by reference in
their entirety.
[0127] The invention also provides DNA vaccines which contain
polynucleotide sequences encoding one or more of the CT491, CT601,
CT687, CT732, CT781, CT808, CT823, CT062, CT104, or CT111
polypeptides, polypeptide fragments, or fusion proteins of the
present invention. The invention further provides DNA vaccines
which contain polynucleotide sequences encoding one or more of any
of the polypeptides, polypeptide fragments, or fusion proteins of
the present invention, and one or more polynucleotide sequences
encoding any of the polypeptides, polypeptide fragments, or fusion
proteins disclosed in U.S. Patent Application Nos. 60/775,462;
60/817,471; and 60/963,215; herein incorporated by reference in
their entirety.
[0128] Preferred polypeptides, polypeptide fragments, or fusion
proteins, for use in a vaccine composition elicit at least a 3-,
4-, 5-, 6-, 7-, 8-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-,
100-, 200-, or 500-fold increase in interferon-.gamma. production
from a population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). Likewise, preferred polynucleotide sequences for use in a
DNA vaccine contain polynucleotide sequences encoding CT491, CT601,
CT687, CT732, CT781, CT808, CT823, CT062, CT104, or CT111
polypeptides, polypeptide fragments, or fusion proteins of the
present invention which elicit at least a 3-, 4-, 5-, 6-, 7-, 8-,
10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 200-, or
500-fold increase in interferon-.gamma. production from a
population of T-lymphocytes compared to the level of
interferon-.gamma. production from T-lymphocytes treated with a
non-antigenic peptide in the same assay (e.g., a peptide which
elicits the lowest measurable value of IFN-.gamma. in the same
assay). The invention further includes a method of inducing an
immunological response in a subject, particularly a human, the
method including inoculating a subject with one or more CT491,
CT601, CT687, CT732, CT781, CT808, CT823, CT062, CT104, or CT111
polypeptide, polypeptide fragment, or fusion protein, or a DNA
vaccine containing a polynucleotide sequence encoding one or more
CT491, CT601, CT687, CT732, CT781, CT808, CT823, CT062, CT104, or
CT111 polypeptide, polypeptide fragment, or fusion protein
disclosed herein, in a suitable carrier for the purpose of inducing
an immune response to prevent or protect a subject from infection,
desirably bacterial infection, and most desirably, C. trachomatis
infection. In addition to the polypeptides, polypeptide fragments,
fusion proteins, and vaccines of the present invention, a subject
may also be inoculated with one or more of the polypeptides,
polypeptide fragments, fusion proteins, and vaccines of U.S. Patent
Application Nos. 60/775,462; 60/817,471; and 60/963,215; herein
incorporated by reference in their entirety.
[0129] The administration of this immunological composition of the
present invention (e.g., DNA vaccine) may be used either
therapeutically in subjects already experiencing an infection, or
may be used prophylactically to prevent an infection. In addition,
the above described vaccines can also be administered to subjects
to generate polyclonal antibodies (purified or isolated from serum
using standard methods) that may be used to passively immunize a
subject. These polyclonal antibodies can also serve as
immunochemical reagents.
[0130] The preparation of vaccines that contain immunogenic
polypeptides is known to one skilled in the art. The CT491, CT601,
CT687, CT732, CT781, CT808, CT823, CT062, CT104, or CT111
polypeptides, polypeptide fragments, or fusion proteins of the
present invention may serve as an antigen for vaccination. Both the
protein-based vaccines described herein and DNA vaccines encoding
the polypeptides, polypeptide fragments, or fusion proteins of the
present invention may be delivered to a subject in order to induce
an immunological response comprising the production of antibodies,
or, in particular, a CD4.sup.+ and/or CD8.sup.+ T cell response in
a subject.
[0131] Protein-based vaccines are typically prepared from one or
more purified recombinant CT491, CT601, CT687, CT732, CT781, CT808,
CT823, CT062, CT104, or CT111 polypeptide, polypeptide fragment, or
fusion protein of the present invention in a physiologically
acceptable diluent vehicle such as water, phosphate-buffered saline
(PBS), acetate-buffered saline (ABS), Ringer's solution, or the
like to form an aqueous composition. The diluent vehicle can also
include oleaginous materials such as squalane, or squalene as is
discussed below.
[0132] Vaccine antigens are usually combined with a
pharmaceutically acceptable carrier, which includes any carrier
that does not include the production of antibodies harmful to the
subject receiving the carrier. Suitable carriers typically comprise
large macromolecules that are slowly metabolized, such as proteins,
polysaccharides, polylactic acids, polyglycolic acids, polymeric
amino acids, amino acid copolymers, lipid aggregates, and inactive
virus particles. Such carriers are well known to those skilled in
the art. These carriers may also function as adjuvants.
[0133] The CT491, CT601, CT687, CT732, CT781, CT808, CT823, CT062,
CT104, or CT111 polypeptides, polypeptide fragments, or fusion
proteins of the present invention may be mixed with excipients that
are pharmaceutically acceptable and compatible with the immunogenic
polypeptide, polypeptide fragment, or fusion protein. Suitable
excipients are, for example, water, saline, dextrose, glycerol,
ethanol, or the like and combinations thereof. In addition, if
desired, a vaccine can contain minor amounts of auxiliary
substances such as wetting or emulsifying agents, or pH buffering
agents that enhance the immunogenic effectiveness of the
composition.
[0134] A protein-based vaccine advantageously also includes an
adjuvant. Suitable adjuvants for vaccines of the present invention
comprise those adjuvants that are capable of enhancing the B cell
and/or T cell response (e.g., CD4.sup.+ and/or CD8.sup.+ T cell
response) to the immunogenic polypeptide or fragment of the present
invention. Adjuvants are well known in the art (see, e.g., Vaccine
Design--The Subunit and Adjuvant Approach, 1995, Pharmaceutical
Biotechnology, Volume 6, Eds. Powell and Newman, Plenum Press, New
York and London).
[0135] Preferred adjuvants for use with the immunogens of the
present invention include aluminum or calcium salts (e.g.,
hydroxide or phosphate salts). A desirable adjuvant is an aluminum
hydroxide gel such as Alhydrogel.TM.. For aluminum hydroxide gels
(alum), the immunogenic polypeptide fragment or fusion protein is
admixed with the adjuvant so that between 50 to 800 .mu.g of
aluminum are present per dose, and preferably, between 400 and 600
.mu.g are present.
[0136] Another adjuvant for use with an immunogenic polypeptide,
polypeptide fragment, or fusion protein of the present invention is
an emulsion. An emulsion can be an oil-in-water emulsion or a
water-in-oil emulsion. In addition to the immunogenic polypeptide,
polypeptide fragment, or fusion protein, such emulsions comprise an
oil phase of squalene, squalane, or the like, as are well known,
and a dispersing agent. Non-ionic dispersing agents are preferred
and such materials include mono- and di-C.sub.12-C.sub.24-fatty
acid esters of sorbitan and mannide such as sorbitan mono-stearate,
sorbitan mono-oleate, and mannide mono-oleate. An
immunogen-containing emulsion is administered as an emulsion.
[0137] Desirably, such emulsions are water-in-oil emulsions that
comprise squalene and mannide mono-oleate (Arlacel.TM. A),
optionally with squalane, emulsified with the immunogenic
polypeptide fragment or fusion protein in an aqueous phase.
Well-known examples of such emulsions include Montanide.TM. ISA-720
and Montanide.TM. ISA-703 (Seppic, Castres, France), each of which
is understood to contain both squalene and squalane, with squalene
predominating in each, but to a lesser extent in Montanide.TM.
ISA-703. Desirably, Montanide.TM. ISA-720 is used, and a ratio of
oil-to-water of 7:3 (w/w) is used. Other preferred oil-in-water
emulsion adjuvants include those disclosed in WO 95/17210 and EP
0399842, herein incorporated by reference.
[0138] The use of small molecule adjuvants is also contemplated
herein. One type of small molecule adjuvant useful herein is a
7-substituted-8-oxo- or 8-sulfo-guanosine derivative described in
U.S. Pat. Nos. 4,539,205; 4,643,992; 5,011,828; and 5,093,318;
herein incorporated by reference. Of these materials,
7-allyl-8-oxoguanosine (loxoribine) is particularly preferred.
Loxoribine has been shown to be particularly effective in inducing
an immunogen-specific response.
[0139] Additional useful adjuvants include monophosphoryl lipid A
(MPL) available from Corixa Corp. (see, U.S. Pat. No. 4,987,237),
CPG available from Coley Pharmaceutical Group, QS21 available from
Aquila Biopharmaceuticals, Inc., SBAS2 available from SmithKline
Beecham, the so-called muramyl dipeptide analogues described in
U.S. Pat. No. 4,767,842, and MF59 available from Chiron Corp. (see,
U.S. Pat. Nos. 5,709,879 and 6,086,901). Further adjuvants include
the active saponin fractions derived from the bark of the South
American tree Quillaja Saponaria Molina (e.g., Quil.TM. A).
Derivatives of Quil.TM. A, for example QS21 (an HPLC purified
fraction derivative of Quil.TM. A), and the method of its
production is disclosed in U.S. Pat. No. 5,057,540. In addition to
QS21 (known as QA21), other fractions such as QA17 are also
disclosed.
[0140] 3-De-O-acylated monophosphoryl lipid A is a well-known
adjuvant manufactured by Ribi Immunochem. The adjuvant contains
three components extracted from bacteria: monophosphoryl lipid
(MPL) A, trehalose dimycolate (TDM), and cell wall skeleton (CWS)
in a 2% squalene/Tween.TM. 80 emulsion. This adjuvant can be
prepared by the methods taught in GB 2122204B. A preferred form of
3-de-O-acylated monophosphoryl lipid A is in the form of an
emulsion having a small particle size of less than 0.2 .mu.m in
diameter (EP 0689454 B1).
[0141] The muramyl dipeptide adjuvants include
N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP; U.S. Pat. No.
4,606,918), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP
11637, referred to as nor-MDP), and
N-acteryl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1',2'-dipalmitoyl-
-sn-glycero-3-hydroxyphosphoryloxy)-ethylamin (CGP) 1983A, referred
to as MTP-PE.
[0142] Desirable adjuvant mixtures include combinations of 3D-MPL
and QS21 (EP0671948 B1), oil-in-water emulsions comprising 3D-MPL
and QS21 (WO 95/17210, PCT/EP98/05714), 3D-MPL formulated with
other carriers (EP 0689454 B1), QS21 formulated in
cholesterol-containing liposomes (WO 96/33739), or
immunostimulatory oligonucleotides (WO 96/02555). Alternative
adjuvants include those described in WO 99/52549 and
non-particulate suspensions of polyoxyethylene ether (UK Patent
Application No. 9807805.8).
[0143] Adjuvants are utilized in an adjuvant amount, which can vary
with the adjuvant, mammal, and the immunogenic CT491, CT601, CT687,
CT732, CT781, CT808, CT823, CT062, CT104, and CT111 polypeptide,
polypeptide fragment, or fusion protein. Typical amounts can vary
from about 1 .mu.g to about 1 mg per immunization. Those skilled in
the art know that appropriate concentrations or amounts can be
readily determined.
[0144] The present invention also provides DNA vaccines containing
polynucleotide sequences encoding the one or more of the
polypeptides, polypeptide fragments, and fusion proteins of the
present invention. Methods for the preparation of DNA vaccines
which contain polynucleotide sequences encoding the CT491, CT601,
CT687, CT732, CT781, CT808, CT823, CT062, CT104, or CT111
polypeptides, polypeptide fragments, or fusion proteins of the
present invention are known in the art. For example, the
polynucleotide sequences encoding the CT491, CT601, CT687, CT732,
CT781, CT808, CT823, CT062, CT104, or CT111 polypeptides,
polypeptide fragments, or fusion proteins of the present invention
may be placed into virus-based vectors, which transfer the CT491,
CT601, CT687, CT732, CT781, CT808, CT823, CT062, CT104, or CT111
polypeptide-, polypeptide fragment-, or fusion protein-encoding
polynucleotide sequence (e.g., DNA or RNA) into a cell, such that
the encoded polypeptide, polypeptide fragment, or fusion protein is
expressed in the cell. Different viral-based vectors that may be
used to deliver the CT491, CT601, CT687, CT732, CT781, CT808,
CT823, CT062, CT104, or CT111 polypeptide-, polypeptide fragment-,
or fusion protein-encoding polynucleotide sequences include
adenoviral vectors and adeno-associated virus-derived vectors,
retroviral vectors, Moloney Murine Leukemia virus-based vectors,
Spleen Necrosis Virus-based vectors, Friend Murine Leukemia-based
vectors, lentivirus-based vectors (Lois et al., Science,
295:868-872, 2002), papova virus-based vectors (e.g., SV40 viral
vectors), Herpes Virus-based vectors, viral vectors that contain or
display the Vesicular Stomatitis Virus G-glycoprotein Spike,
Semliki-Forest virus-based vectors, Hepadnavirus-based vectors, and
Baculovirus-based vectors. Additional, exemplary DNA vaccine
vectors (not intended as limiting) may be found in "Gene Transfer
and Expression in Mammalian Cells," Savvas C. Makrides (Ed.),
Elsevier Science Ltd, 2003. The DNA vaccine may be provided to a
subject in combination with one or more acceptable diluent
vehicles, pharmaceutically acceptable carriers, adjuvants,
excipients, wetting or emulsifying agents, or pH buffering agents
(examples provided herein) and/or one or more nucleic acid delivery
agents (e.g., polymer, lipid, peptide based, degradable particles,
microemulsions, VPLs, attenuated bacterial or viral vectors) using
any route of administration or ex vivo loading.
[0145] Vaccines are conventionally administered parenterally, by
injection, for example, either subcutaneously or intramuscularly.
Typically vaccines are prepared in an injectable form, either as a
liquid solution or a suspension. Solid forms suitable for injection
may also be prepared as emulsions, or with the immunogenic
polypeptide, polypeptide fragment, or fusion protein encapsulated
in liposomes. Additional formulations that are suitable for other
modes of administration include suppositories and, in some cases,
oral formulation or by nasal spray. For suppositories, traditional
binders and carriers can include, for example, polyalkalene glycols
or triglycerides; such suppositories may be formed from mixtures
containing the active ingredient in the range of 0.5% to 10%,
preferably 1-2%. Oral formulations include such normally employed
excipients as, for example, pharmaceutical grades of mannitol,
lactose, starch, magnesium stearate, sodium saccharine, cellulose,
magnesium carbonate, and the like.
[0146] The vaccine composition takes the form of a solution,
suspension, tablet, pill, capsule, sustained release formulation or
powder, and contains an immunogenic effective amount of one or more
of the disclosed CT491, CT601, CT687, CT732, CT781, CT808, CT823,
CT062, CT104, and CT111 polypeptides, polypeptide fragments, fusion
proteins, or DNA vaccines. In a typical composition, an immunogenic
effective amount of the immunogenic polypeptide, polypeptide
fragment, fusion protein, or DNA vaccine is about 1 .mu.g to 10 mg
per dose, and more desirably, about 5 .mu.g to 5 mg per dose.
[0147] A vaccine is typically formulated for parenteral
administration. Exemplary immunizations are carried out
sub-cutaneously (SC), intramuscularly (IM), intravenously (IV),
intraperitoneally (IP), or intra-dermally (ID).
[0148] The immunogenic CT491, CT601, CT687, CT732, CT781, CT808,
CT823, CT062, CT104, or CT111 polypeptides, polypeptide fragments,
or fusion proteins described herein can be formulated into the
vaccine as neutral or salt forms. Pharmaceutically acceptable
salts, include the acid addition salts (formed with the free amino
groups of the polypeptide, polypeptide fragment, or fusion protein)
and are formed with inorganic acids such as, for example,
hydrochloric or phosphoric acids, or such organic acids as acetic,
oxalic, tartaric, mandelic, and the like. Salts formed with the
free carboxyl groups can also be derived from inorganic bases such
as, for example, sodium, potassium, ammonium, calcium, or ferric
hydroxides, and such organic bases as isopropylamine,
trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the
like.
[0149] The vaccines are administered in a manner compatible with
the dosage formulation, and in such amount as are therapeutically
effective and immunogenic. The quantity to be administered depends
on the subject to be treated, capacity of the subject's immune
system to host an immune response, and the degree of protection
desired (e.g., prophylactic treatment or treatment of a patient
with Chlamydia). The precise amount of CT491, CT601, CT687, CT732,
CT781, CT808, CT823, CT062, CT104, and CT111 polypeptide,
polypeptide fragment, fusion protein, or DNA vaccine required to be
administered depends on the judgment of the practitioner and are
peculiar to each subject. However, suitable dosage ranges are of
the order of several hundred of micrograms active ingredient per
subject. Suitable regimes for initial administration and booster
shots are also variable, but are typified by an initial
administration followed in intervals (weeks or months) by a
subsequent injection or other administration.
Pharmaceutical Compositions
[0150] In addition to vaccines, the invention also provides
pharmaceutical compositions that include one or more of the CT491,
CT601, CT687, CT732, CT781, CT808, CT823, CT062, CT104, or CT111
polypeptides, polypeptide fragments, or fusion proteins of the
present invention. The invention further provides pharmaceutical
compositions that include one or more of the polypeptides,
polypeptide fragments, or fusion proteins of the present invention
in combination with one or more of the antigens disclosed in U.S.
Patent Application Nos. 60/775,462; 60/817,471; and 60/963,215;
herein incorporated by reference in their entirety. Such
compositions may be incorporated into a pharmaceutically acceptable
carrier, vehicle, or diluent.
[0151] In one embodiment, the pharmaceutical composition includes a
pharmaceutically acceptable excipient. The compounds of the present
invention may be administered by any suitable means, depending for
example, on their intended use, as is well known in the art, based
on the present description. For example, if the polypeptides,
polypeptide fragments, or fusion proteins of the present invention
are to be administered orally, they may be formulated as tablets,
capsules, granules, powders, or syrups. Alternatively, formulations
of the present invention may be administered parenterally as
injections (intravenous, intramuscular, or subcutaneous), drop
infusion preparations, or suppositories. For application by the
ophthalmic mucous membrane route, the compounds of the present
invention may be formulated as eye drops or eye ointments. Aqueous
solutions are generally preferred for ocular administration, based
on ease of formulation, biological compatibility, as well as a
subject's ability to easily administer such compositions, for
example, by means of instilling one to two drops of the solutions
in the eye. However, the compositions may also be suspensions,
viscous or semi-viscous gels, or other types of solid or semi-solid
compositions.
[0152] The above-described formulations may be prepared by
conventional means, and, if desired, the compounds may be mixed
with any conventional additive, such as an excipient, a binder, a
disintegrating agent, a lubricant, a corrigent, a solubilizing
agent, a suspension aid, an emulsifying agent, or a coating
agent.
[0153] Subject compounds may be suitable for oral, nasal, topical
(including buccal and sublingual), rectal, vaginal, aerosol, and/or
parenteral administration. The formulations may conveniently be
presented in unit dosage form and may be prepared by any methods
well known in the art of pharmacy. The amount of agent that may be
combined with a carrier material to produce a single dose varies
depending upon the subject being treated, and the particular mode
of administration.
[0154] Pharmaceutical compositions of this invention suitable for
parenteral administration includes one or more components of a
supplement in combination with one or more pharmaceutically
acceptable sterile isotonic aqueous or non-aqueous solutions,
dispersions, suspensions or emulsions, or sterile powders which may
be reconstituted into sterile injectable solutions or dispersions
just prior to use, which may contain antioxidants, buffers,
bacteriostats, solutes which render the formulation isotonic with
the blood of the intended recipient, or suspending or thickening
agents.
Methods of Treating Bacterial Infections
[0155] The polypeptide fragments, fusion proteins, pharmaceutical
compositions, and vaccines described herein may be used in a
variety of treatments of diseases including a bacterial infection,
most preferably a C. trachomatis infection in a subject. Those
skilled in the art will understand, the dosage of any composition
described herein will vary depending, for example, on the symptoms,
age, and body weight of the subject, the nature and severity of the
infection to be treated or prevented, the route of administration,
and the form of the supplement. Any of the subject formulations may
be administered in any suitable dose, such as, for example, in a
single dose or in divided doses. Dosages for the compounds of the
present invention, alone or together with any other compound of the
present invention, or in combination with any compound deemed
useful for the particular infection to be treated, may be readily
determined by techniques known to those skilled in the art. Also,
the present invention provides mixtures of more than one subject
compound, as well as other therapeutic agents.
[0156] The combined use of several compounds of the present
invention, or alternatively other therapeutic agents, may reduce
the required dosage for any individual component because the onset
and duration of effect of the different components may be
complimentary. In such combined therapy, the different active
agents may be delivered together or separately, and simultaneously
or at different times within the day.
[0157] Different bacterial infections that may be treated or
prevented with the present invention include: Chlamydia pneumoniae,
Chlamydia psittaci, and Chlamydia trachomatis.
Therapeutic Antibodies and T-Cell Depletion
[0158] Alternatively, the immune response to Chlamydia, rather than
the infection itself, may be responsible for symptoms that
accompany infection, including sterility and pelvic inflammatory
disease in a subject. In this case, it may be desirable to limit
the immune response by a subset of CD4.sup.+ or CD8.sup.+ T cells
within an infected subject. Antibodies which specifically recognize
T cell clones targeted to the polypeptides, polypeptide fragments,
or fusion proteins of the present invention, may therefore be
useful in treating or preventing deleterious effects associated
with Chlamydia infection. Methods for selective depletion of
specific populations of T cells are described, for example, in
Weinberg et al. (Nature Med. 2:183-189, 1966).
[0159] The following Example is meant to illustrate the invention
and should not be construed as limiting.
Example 1
Determining Whether a C. trachomatis Polypeptide, Polypeptide
Fragment, or Fusion Protein is Immunogenic
Methods
[0160] A library of cells or viruses containing polynucleotides
encoding C. trachomatis polypeptides, polypeptide fragments, or
fusion proteins may be screened to determine which of the
polypeptides, polypeptide fragments, or fusion proteins encoded by
the polynucleotides are immunogenic. This may be accomplished by
contacting each member of the library with a second cell (e.g., a
macrophage or antigen presenting cell) capable of endocytosing the
cell of the C. trachomatis library, and displaying portions of the
expressed polypeptide of the library on the surface of the second
cell (see, e.g., U.S. Pat. No. 6,008,415). The second cell is then
contacted with a C. trachomatis-specific T cell (e.g., a C.
trachomatis-specific CD4.sup.+ or CD8.sup.+ T cell) from an
organism previously infected with C. trachomatis. The second cell
may also be fixed (e.g., using paraformaldehyde) prior to
contacting with a C. trachomatis-specific T cell. A C.
trachomatis-specific T cell capable of binding a presented portion
of the C. trachomatis protein, will result in secretion of
cytokines. Cytokine secretion (e.g., secretion of IFN-.gamma.,
IL-2, or TNF) may be assayed for as known in the art, for example,
using an ELISA assay.
[0161] In particular, murine H2.sup.b bone marrow-derived
macrophages (BMMs) were seeded at a density of 1.times.10.sup.5
cells/well in 96-well plates. Fourteen to sixteen hours later, an
aliquot of a frozen C. trachomatis library was thawed. The media
was aspirated from the BMMs and replaced with a library aliquot and
60 .mu.L of fresh RP-10 media. After 1 hour at 37.degree. C., the
BMMs were washed with PBS, 100 .mu.L of RP-10 media added, and the
cells incubated an additional hour at 37.degree. C. The BMMs were
then fixed with 1% paraformaldehyde for 15 minutes and washed
extensively with PBS. BMM fixation was found to greatly reduce the
background level of IFN-.gamma. secretion by T cells. T cells
(either C. trachomatis-specific CD4.sup.+ or CD8.sup.+ murine T
cells; 1.times.10.sup.5) were added to each well in 200 .mu.L of
RP-10 media. Plates were incubated for 18-24 hours at 37.degree. C.
and the amount of IFN-.gamma. in the supernatant of each well
determined through the use of an IFN-.gamma. ELISA assay
(Endogen).
[0162] Another way to identify an antigenic peptide is to pulse the
polypeptide, polypeptide fragment, or fusion protein onto
macrophages and screen for their ability to activate C.
trachomatis-specific CD4.sup.+ or CD8.sup.+ murine T cells (as
described above). Peptides used in such assays can be synthesized
using methods known in the art. A polypeptide, polypeptide
fragment, or fusion protein that is capable of activating the C.
trachomatis-specific CD4.sup.+ or CD8.sup.+ murine T cells is
deemed immunogenic.
C. trachomatis-Specific CD8.sup.+ Murine T Cells
[0163] An example of a protocol that may be used to produce C.
trachomatis-specific CD8.sup.+ murine T cells is provided
below.
[0164] Pools of activated CD8.sup.+ murine T cells for use in the
identification of immunogenic C. trachomatis polypeptides,
polypeptide fragments, and fusion proteins may be obtained using
methods known in the art. Typically, in screening for antigens to
pathogenic organisms, CD8.sup.+ T cells are prepared from a mammal
previously infected with the pathogenic organism. This preparation
contains CD8.sup.+ T cells specific for antigens from the
pathogen.
[0165] C. trachomatis-specific CD8.sup.+ T cells were harvested
from mice as follows. A C57BL/6 mouse was injected
intraperitoneally with 10.sup.7 infection-forming units of C.
trachomatis. Fourteen days later the mouse was euthanized and the
spleen was harvested. The spleen was mashed through a 70 .mu.m
screen to create a single cell solution of splenocytes. The
CD8.sup.+ T cells were isolated from the splenocytes using anti-CD8
antibodies bound to MACS.TM. magnetic beads and separation
protocols standard in the art (see, for e.g., MACS.TM. technology
available from Miltenyi Biotec Inc., Auburn, Calif.). The isolated
CD8.sup.+ cells were added to macrophages of the same haplotype
(H2.sup.b), which were infected with C. trachomatis 18 hours prior
in a 24-well dish. Irradiated splenocytes from a naive mouse
(C57BL/6) were added as feeder cells in media containing IL-2. The
cells were incubated for 10 days during which the C.
trachomatis-specific CD8.sup.+ T cells were stimulated by the
infected macrophages and replicated. On day 10, the CD8.sup.+ T
cells were stimulated again using macrophages infected with C.
trachomatis (18 hours prior), and irradiated splenocytes. This
procedure was repeated until sufficient amounts of CD8.sup.+ T
cells were present to screen the library.
[0166] CD8.sup.+ T cells may also be cloned from a human subject as
described by, for example, Hassell et al. (Immunology 79: 513-519,
1993).
C. trachomatis-Specific Murine CD4.sup.+ T Cells
[0167] Activated CD4.sup.+ murine T cells for use in the
identification of immunogenic C. trachomatis polypeptides,
polypeptide fragments, and fusion proteins may be obtained using
methods known in the art. Splenocytes from mice were isolated 21
days after infection with C. trachomatis serovar L2 and cultured
with irradiated (2,000 rad) bone marrow-derived dendritic cells,
UV-inactivated C. trachomatis serovar L2, and naive syngeneic
splenocytes in RP-10 (RPMI medium 1640 supplemented with 10% fetal
calf serum, L-glutamine, HEPES, 50 .mu.M 2-.beta.-mercaptoethanol,
50 units/ml penicillin, and 50 .mu.g/ml streptomycin) with
.alpha.-methyl mannoside and 5% supernatant from Con A-stimulated
rat spleen cells. CD8.sup.+ T cells were depleted from the culture
by using Dynabeads Mouse CD8 (Invitrogen, Carlsbad, Calif.). The
CD4.sup.+ T cells were restimulated every 7 days with C.
trachomatis-pulsed bone marrow-derived dendritic cells. Once a C.
trachomatis-specific CD4.sup.+ cell line was established, a
CD4.sup.+ T cell clone was isolated by limiting dilution.
[0168] CD4.sup.+ T cells may also be cloned from a human subject as
described by, for example, Hassell et al. (Immunology 79: 513-519,
1993).
[0169] This application is related to U.S. Application No.
60/775,462 filed Feb. 21, 2007; U.S. Application No. 60/817,471
filed Jun. 29, 2006; and U.S. Application No. 60/963,215 filed Aug.
3, 2007. The disclosures of U.S. Application Nos. 60/775,462;
60/817,471; and 60/963,215 are hereby incorporated by reference in
their entirety.
[0170] All patents, patent applications, patent application
publications, and other cited references are hereby incorporated by
reference to the same extent as if each independent patent, patent
application, or publication was specifically and individually
indicated to be incorporated by reference.
Sequence CWU 1
1
141464PRTChlamydia trachomatis 1Met Lys Glu Glu Ser Pro Ala Glu Val
Leu Gln Lys Val Lys Glu His 1 5 10 15 Lys Arg Arg Glu Gly Pro Leu
Ser Leu Glu Lys Glu Val Ser Glu Asp 20 25 30 Ser Ala Val Ala Thr
Glu Glu Lys Glu Thr Ser Gln Pro Val Ala Val 35 40 45 Thr Lys Ile
Ala Lys Leu Gln Arg Met Gly Ile Asn Glu Leu Asn Val 50 55 60 Leu
Ala Arg Gln Tyr Gly Val Lys Asn Val Gly Ser Leu Thr Lys Ser 65 70
75 80 Gln Val Val Phe Glu Ile Val Lys Ala Lys Ser Glu Arg Pro Asp
Glu 85 90 95 Phe Leu Ile Gly Glu Gly Val Leu Glu Val Leu Pro Asp
Gly Phe Gly 100 105 110 Phe Leu Arg Ser Pro Thr Tyr Asn Tyr Leu Pro
Ser Ala Glu Asp Ile 115 120 125 Tyr Val Ser Pro Ala Gln Ile Arg Arg
Phe Asp Leu Lys Lys Gly Asp 130 135 140 Thr Ile Val Gly Thr Ile Arg
Ser Pro Lys Glu Lys Glu Lys Tyr Phe 145 150 155 160 Ala Leu Leu Lys
Val Asp Lys Ile Asn Gly Ser Thr Pro Asp Lys Ala 165 170 175 Lys Glu
Arg Val Leu Phe Glu Asn Leu Thr Pro Leu His Pro Asn Glu 180 185 190
Arg Leu Ile Met Glu Met Gly Lys Glu Asn Leu Ala Glu Arg Val Leu 195
200 205 Asp Leu Thr Ala Pro Ile Gly Lys Gly Gln Arg Gly Leu Ile Val
Ala 210 215 220 Pro Pro Arg Ser Gly Lys Thr Val Ile Leu Gln Ser Ile
Ala His Ala 225 230 235 240 Ile Ala Val Asn Asn Pro Asp Ala Glu Leu
Ile Val Leu Leu Ile Asp 245 250 255 Glu Arg Pro Glu Glu Val Thr Asp
Met Ile Arg Gln Val Arg Gly Glu 260 265 270 Val Val Ala Ser Thr Phe
Asp Glu Gln Pro Asp Arg His Ile Gln Val 275 280 285 Thr Glu Met Val
Ile Glu Lys Ala Arg Arg Leu Val Glu His Gly Lys 290 295 300 Asp Val
Val Ile Leu Leu Asp Ser Ile Thr Arg Leu Ala Arg Ala Tyr 305 310 315
320 Asn Thr Val Gln Pro His Ser Gly Lys Ile Leu Thr Gly Gly Val Asp
325 330 335 Ala Ser Ala Leu His Lys Pro Lys Arg Phe Phe Gly Ala Ala
Arg Asn 340 345 350 Ile Glu Gly Gly Gly Ser Leu Thr Ile Leu Ala Thr
Ala Leu Ile Asp 355 360 365 Thr Gly Ser Arg Met Asp Glu Val Ile Phe
Glu Glu Phe Lys Gly Thr 370 375 380 Gly Asn Met Glu Leu Val Leu Asp
Arg His Leu Ser Asp Arg Arg Ile 385 390 395 400 Tyr Pro Ala Ile Asp
Leu Ile Lys Ser Gly Thr Arg Lys Glu Glu Leu 405 410 415 Leu Tyr His
Pro Gly Glu Leu Glu Lys Ile Arg Leu Phe Arg Gln Ala 420 425 430 Ile
Ala Gly Leu Thr Ala Ile Asp Ala Met His Leu Leu Leu Gly Arg 435 440
445 Leu Lys Lys Thr Asn Ser Asn Thr Glu Phe Leu Leu Ser Leu Lys Asp
450 455 460 2200PRTChlamydia trachomatis 2Met Leu Ala Asn Arg Leu
Phe Leu Ile Thr Leu Leu Gly Leu Ser Ser 1 5 10 15 Ser Val Tyr Gly
Ala Gly Lys Ala Pro Ser Leu Gln Ala Ile Leu Ala 20 25 30 Glu Val
Glu Asp Thr Ser Ser Arg Leu His Ala His His Asn Glu Leu 35 40 45
Ala Met Ile Ser Glu Arg Leu Asp Glu Gln Asp Thr Lys Leu Gln Gln 50
55 60 Leu Ser Ser Thr Gln Asp His Asn Leu Pro Arg Gln Val Gln Arg
Leu 65 70 75 80 Glu Thr Asp Gln Lys Ala Leu Ala Lys Thr Leu Ala Ile
Leu Ser Gln 85 90 95 Ser Val Gln Asp Ile Arg Ser Ser Val Gln Asn
Lys Leu Gln Glu Ile 100 105 110 Gln Gln Glu Gln Lys Lys Leu Ala Gln
Asn Leu Arg Ala Leu Arg Asn 115 120 125 Ser Leu Gln Ala Leu Val Asp
Gly Ser Ser Pro Glu Asn Tyr Ile Asp 130 135 140 Phe Leu Thr Gly Glu
Thr Pro Glu His Ile His Ile Val Lys Gln Gly 145 150 155 160 Glu Thr
Leu Ser Lys Ile Ala Ser Lys Tyr Asn Ile Pro Val Val Glu 165 170 175
Leu Lys Lys Leu Asn Lys Leu Asn Ser Asp Thr Ile Phe Thr Asp Gln 180
185 190 Arg Ile Arg Leu Pro Lys Lys Lys 195 200 3401PRTChlamydia
trachomatis 3Met Tyr Asn Val Lys Lys Asp Phe Pro Ile Phe Lys Asn
Gln Gly Asp 1 5 10 15 Pro Tyr Val Tyr Leu Asp Ser Ala Ala Thr Thr
His Lys Pro Gln Cys 20 25 30 Val Ile Asp Ser Ile Val Asp Tyr Tyr
Ser Ser Ser Tyr Ala Thr Val 35 40 45 Asn Arg Ala Leu Tyr Thr Ala
Ser His Asp Ile Thr Phe Ala His Trp 50 55 60 Gln Val Arg Ser Lys
Val Gly Ser Trp Ile Gly Ala Gln Tyr Asp Gln 65 70 75 80 Glu Ile Ile
Phe Thr Arg Gly Thr Thr Ser Ser Leu Asn Leu Leu Ala 85 90 95 Ile
Ala Ala Asn Asp Ser Trp Leu Ala Gly Gly Thr Val Val Ile Ser 100 105
110 Glu Ala Glu His His Ala Asn Leu Val Ser Trp Glu Leu Ala Cys Gln
115 120 125 Arg Ser Gly Ala Thr Ile Lys Lys Val Arg Val Asp Asp Glu
Gly Met 130 135 140 Val Asp Cys Ser His Leu Glu Gln Leu Leu Lys Gln
Gly Val Gln Leu 145 150 155 160 Val Ser Leu Ala His Val Ser Asn Val
Ser Gly Ala Val Leu Pro Leu 165 170 175 Pro Glu Ile Ala His Leu Val
His Arg Tyr Glu Ala Leu Phe Ala Val 180 185 190 Asp Gly Ala Gln Gly
Val Gly Lys Gly Pro Leu Asn Leu Ser Glu Trp 195 200 205 Gly Val Asp
Phe Tyr Ala Phe Ser Gly His Lys Leu Tyr Ala Pro Thr 210 215 220 Gly
Ile Gly Val Leu Tyr Gly Lys Lys Glu Leu Leu Glu Ser Leu Pro 225 230
235 240 Pro Val Glu Gly Gly Gly Asp Met Val Ile Val Tyr Asp Phe Glu
Glu 245 250 255 Leu Ser Tyr Gln Glu Pro Pro Leu Arg Phe Glu Ala Gly
Thr Pro His 260 265 270 Ile Ala Gly Val Leu Gly Leu Gly Ala Ala Ile
Asp Tyr Leu Gln Ala 275 280 285 Leu Pro Phe Ser Ile Thr Asp Arg Leu
Thr Glu Leu Thr His Phe Leu 290 295 300 Tyr Glu Gln Leu Leu Thr Val
Pro Gly Ile Gln Ile Ile Gly Pro Lys 305 310 315 320 Gln Gly Ala Ala
Arg Gly Ser Leu Cys Ser Ile Ser Ile Pro Gly Val 325 330 335 Gln Ala
Ser Asp Leu Gly Phe Leu Leu Asp Gly Arg Gly Ile Ser Val 340 345 350
Arg Ser Gly His Gln Cys Ser Gln Pro Ala Met Val Arg Trp Asp Leu 355
360 365 Gly His Val Leu Arg Ala Ser Leu Gly Ile Tyr Asn Glu Gln Gln
Asp 370 375 380 Ile Leu Leu Phe Val Glu Ala Leu Lys Asp Ile Leu Arg
Ala Tyr Arg 385 390 395 400 Ser 4157PRTChlamydia Trachomatis 4Met
Lys Pro Leu Lys Gly Cys Pro Val Ala Lys Asp Val Arg Val Ala 1 5 10
15 Ile Val Gly Ser Cys Phe Asn Ser Pro Ile Ala Asp Arg Leu Val Ala
20 25 30 Gly Ala Gln Glu Thr Phe Phe Asp Phe Gly Gly Asp Pro Ser
Ser Leu 35 40 45 Thr Ile Val Arg Val Pro Gly Ala Phe Glu Ile Pro
Cys Ala Ile Lys 50 55 60 Lys Leu Leu Ser Thr Ser Gly Gln Phe His
Ala Val Val Ala Cys Gly 65 70 75 80 Val Leu Ile Gln Gly Glu Thr Ser
His Tyr Glu His Ile Ala Asp Ser 85 90 95 Val Ala Ala Gly Val Ser
Arg Leu Ser Leu Asp Phe Cys Leu Pro Ile 100 105 110 Thr Phe Ser Val
Ile Thr Ala Pro Asn Met Glu Ala Ala Trp Glu Arg 115 120 125 Ala Gly
Ile Lys Gly Pro Asn Leu Gly Ala Ser Gly Met Lys Thr Ala 130 135 140
Leu Glu Met Ala Ser Leu Phe Ser Leu Ile Gly Lys Glu 145 150 155
5526PRTChlamydia trachomatis 5Met Ser Val Glu Val Glu Tyr Leu Gln
His Glu Asp Tyr Leu Tyr Arg 1 5 10 15 Thr Ser Lys Leu Lys Glu Ile
Arg Asp Leu Gly Ile Asn Pro Tyr Pro 20 25 30 Tyr Gln Tyr Thr Asp
Cys Leu Glu Val Gln Glu Ile Arg Asn Gln Phe 35 40 45 Val Asp Asn
Glu Leu Gly Asp Ser Glu Ala Ala Phe Arg Lys Glu Thr 50 55 60 Pro
Lys Val Arg Phe Ala Gly Arg Leu Val Leu Phe Arg Ser Met Gly 65 70
75 80 Lys Asn Ser Phe Gly Gln Ile Leu Asp Asn Asp Ala Lys Ile Gln
Val 85 90 95 Met Phe Asn Arg Asp Phe Ser Ala Val Ala Gly Leu Ala
Ala Asp Ala 100 105 110 Gly Ile Ser Pro Ile Lys Phe Ile Glu Lys Lys
Leu Asp Leu Gly Asp 115 120 125 Ile Leu Gly Leu Glu Gly Tyr Leu Phe
Phe Thr His Ser Gly Glu Leu 130 135 140 Thr Val Leu Val Glu Thr Val
Thr Leu Leu Cys Lys Ser Leu Ile Ser 145 150 155 160 Leu Pro Asp Lys
His Ala Gly Leu Ala Asp Lys Glu Ile Arg Tyr Arg 165 170 175 Lys Arg
Trp Ala Asp Leu Ile Ser Ser Glu Asp Val Arg Lys Thr Phe 180 185 190
Leu Thr Arg Ser Arg Ile Leu Lys Leu Ile Arg Glu Tyr Met Asp Gln 195
200 205 Gln Ser Phe Leu Glu Val Glu Thr Pro Ile Leu Gln Thr Ile Tyr
Gly 210 215 220 Gly Ala Glu Ala Thr Pro Phe Val Thr Thr Leu Gln Ala
Leu His Ala 225 230 235 240 Glu Met Phe Leu Arg Ile Ser Leu Glu Ile
Ala Leu Lys Lys Leu Leu 245 250 255 Val Gly Gly Met Ser Arg Val Tyr
Glu Ile Gly Lys Val Phe Arg Asn 260 265 270 Glu Gly Ile Asp Arg Thr
His Asn Pro Glu Phe Thr Met Ile Glu Ala 275 280 285 Tyr Ala Ala Tyr
Trp Asp Tyr Asn Asp Val Met Lys Cys Val Glu Asn 290 295 300 Leu Val
Glu Tyr Ile Val Arg Ala Leu Asn Asn Gly Glu Thr Gln Val 305 310 315
320 Gln Tyr Ser His Leu Lys Ser Gly Pro Gln Val Val Asp Phe Lys Ala
325 330 335 Pro Trp Ile Arg Met Thr Met Lys Glu Ser Ile Ser Val Tyr
Gly Gly 340 345 350 Val Asp Val Asp Leu His Ala Asp His Glu Leu Arg
Lys Ile Leu Glu 355 360 365 Thr Gln Thr Ser Leu Pro Glu Lys Thr Tyr
Val His Ala Ser Arg Gly 370 375 380 Glu Leu Ile Ala Leu Leu Phe Asp
Glu Leu Val Cys Asp Lys Leu Ile 385 390 395 400 Ala Pro His His Ile
Thr Asp His Pro Leu Glu Thr Thr Pro Leu Cys 405 410 415 Lys Thr Leu
Arg Ser Gly Asp Glu Thr Leu Val Glu Arg Phe Glu Ser 420 425 430 Phe
Cys Leu Gly Lys Glu Leu Cys Asn Ala Tyr Ser Glu Leu Asn Asp 435 440
445 Pro Leu Gln Gln Arg Lys Leu Leu Glu Glu Gln Met Arg Lys Lys Ala
450 455 460 Leu Asn Pro Asp Ser Glu Tyr His Pro Ile Asp Glu Glu Phe
Leu Glu 465 470 475 480 Ala Leu Cys Gln Gly Met Pro Pro Ala Gly Gly
Phe Gly Ile Gly Ile 485 490 495 Asp Arg Leu Val Met Met Leu Thr Asp
Ala Ala Ser Ile Arg Asp Val 500 505 510 Leu Phe Phe Pro Val Met Arg
Arg Ile Glu Ala Lys Lys Asp 515 520 525 6512PRTChlamydia
trachomatis 6Met Glu Asn Asp Ile Leu Leu Asn Ile Glu Ser Lys Glu
Ile Arg Tyr 1 5 10 15 Ala His Leu Lys Asn Gly Gln Leu Phe Asp Leu
Ile Ile Glu Arg Lys 20 25 30 Lys Ile Arg Gln Leu Lys Gly Asn Ile
Tyr Arg Gly Arg Val Thr Asn 35 40 45 Ile Leu Arg Asn Ile Gln Ser
Ala Phe Ile Asn Ile Asp Glu Arg Glu 50 55 60 Asn Gly Phe Ile His
Ile Ser Asp Val Leu Glu Asn Ser Lys Lys Phe 65 70 75 80 Glu Gln Met
Phe Asp Ile Asp Ser Asp Ala Asp His Ala Glu Pro Gln 85 90 95 Pro
Glu Glu Thr Ser Lys Ala Pro Ile Glu Glu Leu Leu Lys Leu Asp 100 105
110 Ser Pro Val Leu Val Gln Val Val Lys Glu Pro Ile Gly Thr Lys Gly
115 120 125 Ala Arg Leu Thr Ser Asn Ile Ser Ile Pro Gly Arg Tyr Leu
Val Leu 130 135 140 Leu Pro Asn Ser Pro His Arg Gly Val Ser Arg Lys
Ile Glu Asp Pro 145 150 155 160 Leu Met Arg Asp Gln Leu Lys Gln Leu
Ile Arg Ser Phe Glu Met Pro 165 170 175 Gln Asn Met Gly Leu Ile Cys
Arg Thr Ala Ser Ile Ser Ala Ser Thr 180 185 190 Glu Thr Leu Ile Asn
Glu Ala Gln Asp Leu Leu Asn Thr Trp Gln Ser 195 200 205 Ile Leu Glu
Lys Phe Tyr Ser Pro Asp His Pro Ser Leu Leu Tyr Glu 210 215 220 Glu
Thr Asp Ile Leu Lys Lys Ala Val Met Thr Cys Val Asp Lys Ser 225 230
235 240 Tyr Lys Arg Leu Leu Ile Asp Asp Tyr Ala Thr Tyr Gln Lys Cys
Lys 245 250 255 Arg Leu Leu Gly Lys Tyr Ser Pro Asp Thr Thr Val Lys
Ile Glu Tyr 260 265 270 Tyr Arg Asp Ser Val Pro Met Phe Glu Arg Phe
Asn Ile Glu Lys Glu 275 280 285 Ile Asp Arg Ala Thr Lys Arg Lys Ile
Trp Leu Ser Ser Gly Gly Tyr 290 295 300 Leu Phe Phe Asp Lys Thr Glu
Ala Met His Thr Ile Asp Val Asn Ser 305 310 315 320 Gly Arg Ser Thr
Gln Leu Glu Asn Gly Val Glu Glu Thr Leu Val Gln 325 330 335 Ile Asn
Leu Glu Ala Ala Glu Glu Ile Ala Arg Gln Leu Arg Leu Arg 340 345 350
Asn Ile Gly Gly Leu Val Ile Ile Asp Phe Ile Asp Met Lys Ser Arg 355
360 365 Lys Asn Gln Arg Arg Val Leu Glu Arg Leu Lys Glu His Met Lys
Tyr 370 375 380 Asp Ala Ala Arg Cys Thr Ile Leu Ser Met Ser Glu Phe
Gly Leu Val 385 390 395 400 Glu Met Thr Arg Gln Arg Asn Arg Glu Ser
Leu Met Gln Thr Leu Phe 405 410 415 Thr Thr Cys Pro Tyr Cys Asn Gly
Asn Ala Ile Ile Lys Thr Ser Glu 420 425 430 Ser Ile Leu Ile Glu Ile
Glu Arg Asp Leu Lys Lys Ile Ile Lys His 435 440 445 Lys Glu His Thr
Asn Leu Cys Leu Val Val His Pro Glu Ile Ala His 450 455 460 Tyr Met
Lys Gln Glu Gln Asp Asp Val Glu Leu Ile Arg Leu Ala Lys 465 470 475
480 Gln Leu Lys Ala Lys Leu Gln Ile Asn Thr Ser Asp Ser Ile His Leu
485 490 495 Asn His Tyr Gln Phe Phe Ser Leu Ile Thr Gly Glu Gly Ile
Glu Leu 500 505 510 7497PRTChlamydia trachomatis 7Met Met Lys Arg
Leu Leu Cys Val Leu Leu Ser Thr Ser Val Phe Ser 1 5 10 15 Ser
Pro Met Leu Gly Tyr Ser Ala Ser Lys Lys Asp Ser Lys Ala Asp 20 25
30 Ile Cys Leu Ala Val Ser Ser Gly Asp Gln Glu Val Ser Gln Glu Asp
35 40 45 Leu Leu Lys Glu Val Ser Arg Gly Phe Ser Arg Val Ala Ala
Lys Ala 50 55 60 Thr Pro Gly Val Val Tyr Ile Glu Asn Phe Pro Lys
Thr Gly Asn Gln 65 70 75 80 Ala Ile Ala Ser Pro Gly Asn Lys Arg Gly
Phe Gln Glu Asn Pro Phe 85 90 95 Asp Tyr Phe Asn Asp Glu Phe Phe
Asn Arg Phe Phe Gly Leu Pro Ser 100 105 110 His Arg Glu Gln Gln Arg
Pro Gln Gln Arg Asp Ala Val Arg Gly Thr 115 120 125 Gly Phe Ile Val
Ser Glu Asp Gly Tyr Val Val Thr Asn His His Val 130 135 140 Val Glu
Asp Ala Gly Lys Ile His Val Thr Leu His Asp Gly Gln Lys 145 150 155
160 Tyr Thr Ala Lys Ile Val Gly Leu Asp Pro Lys Thr Asp Leu Ala Val
165 170 175 Ile Lys Ile Gln Ala Glu Lys Leu Pro Phe Leu Thr Phe Gly
Asn Ser 180 185 190 Asp Gln Leu Gln Ile Gly Asp Trp Ala Ile Ala Ile
Gly Asn Pro Phe 195 200 205 Gly Leu Gln Ala Thr Val Thr Val Gly Val
Ile Ser Ala Lys Gly Arg 210 215 220 Asn Gln Leu His Ile Val Asp Phe
Glu Asp Phe Ile Gln Thr Asp Ala 225 230 235 240 Ala Ile Asn Pro Gly
Asn Ser Gly Gly Pro Leu Leu Asn Ile Asn Gly 245 250 255 Gln Val Ile
Gly Val Asn Thr Ala Ile Val Ser Gly Ser Gly Gly Tyr 260 265 270 Ile
Gly Ile Gly Phe Ala Ile Pro Ser Leu Met Ala Lys Arg Val Ile 275 280
285 Asp Gln Leu Ile Ser Asp Gly Gln Val Thr Arg Gly Phe Leu Gly Val
290 295 300 Thr Leu Gln Pro Ile Asp Ser Glu Leu Ala Thr Cys Tyr Lys
Leu Glu 305 310 315 320 Lys Val Tyr Gly Ala Leu Val Thr Asp Val Val
Lys Gly Ser Pro Ala 325 330 335 Glu Lys Ala Gly Leu Arg Gln Glu Asp
Val Ile Val Ala Tyr Asn Gly 340 345 350 Lys Glu Val Glu Ser Leu Ser
Ala Leu Arg Asn Ala Ile Ser Leu Met 355 360 365 Met Pro Gly Thr Arg
Val Val Leu Lys Ile Val Arg Glu Gly Lys Thr 370 375 380 Ile Glu Ile
Pro Val Thr Val Thr Gln Ile Pro Thr Glu Asp Gly Val 385 390 395 400
Ser Ala Leu Gln Lys Met Gly Val Arg Val Gln Asn Ile Thr Pro Glu 405
410 415 Ile Cys Lys Lys Leu Gly Leu Ala Ala Asp Thr Arg Gly Ile Leu
Val 420 425 430 Val Ala Val Glu Ala Gly Ser Pro Ala Ala Ser Ala Gly
Val Ala Pro 435 440 445 Gly Gln Leu Ile Leu Ala Val Asn Arg Gln Arg
Val Ala Ser Val Glu 450 455 460 Glu Leu Asn Gln Val Leu Lys Asn Ser
Lys Gly Glu Asn Val Leu Leu 465 470 475 480 Met Val Ser Gln Gly Asp
Val Val Arg Phe Ile Val Leu Lys Ser Asp 485 490 495 Glu
8412PRTChlamydia trachomatis 8Met Gln Gln Leu Ile Asp Asn Leu Lys
Lys Arg Gly Ile Leu Asp Asn 1 5 10 15 Ser Ser Ala Gly Leu Glu Ser
Leu Thr Val Pro Val Ser Ala Tyr Leu 20 25 30 Gly Phe Asp Pro Thr
Ala Pro Ser Leu His Ile Gly His Trp Ile Gly 35 40 45 Ile Cys Phe
Leu Arg Arg Leu Ala Ala Tyr Gly Ile Thr Pro Val Ala 50 55 60 Leu
Val Gly Gly Ala Thr Gly Met Ile Gly Asp Pro Ser Gly Lys Ser 65 70
75 80 Val Glu Arg Ser Leu Leu Asp Gln Ala Gln Val Leu Asp Asn Ser
Lys 85 90 95 Lys Ile Ala Ala Ala Leu Ala Ser Tyr Leu Pro Gly Ile
Arg Ile Val 100 105 110 Asn Asn Ala Asp Trp Leu Gly Ser Leu Ser Met
Val Asp Phe Leu Arg 115 120 125 Asp Val Gly Lys His Phe Arg Leu Gly
Ser Met Leu Ala Lys Asp Val 130 135 140 Val Lys Gln Arg Val Tyr Ser
Glu Glu Gly Ile Ser Tyr Thr Glu Phe 145 150 155 160 Ser Tyr Leu Leu
Leu Gln Ser Tyr Asp Phe Ala His Leu Phe Lys Glu 165 170 175 His Asn
Val Val Leu Gln Cys Gly Gly Ser Asp Gln Trp Gly Asn Ile 180 185 190
Thr Ser Gly Ile Asp Tyr Ile Arg Arg Arg Gly Leu Gly Gln Ala Tyr 195
200 205 Gly Leu Thr Tyr Pro Leu Leu Thr Asp Ser Lys Gly Lys Lys Ile
Gly 210 215 220 Lys Thr Glu Ser Gly Thr Ile Trp Leu Asp Pro Ala Leu
Thr Pro Pro 225 230 235 240 Tyr Glu Leu Phe Gln Tyr Phe Leu Arg Leu
Pro Asp Gln Glu Ile Ser 245 250 255 Lys Val Met Arg Thr Leu Thr Leu
Leu Asp Asn Glu Glu Ile Phe Ala 260 265 270 Leu Asp Glu Arg Leu Thr
Ser Asp Pro Gln Ala Val Lys Lys Tyr Ile 275 280 285 Ala Glu Val Ile
Val Lys Asp Val His Gly Ser Glu Gly Leu Ala Gln 290 295 300 Ala Gln
Ala Ala Thr Glu Ser Phe Phe Ala Ser Lys Gly Lys Ser Ile 305 310 315
320 Thr Glu Ala Glu Leu Val Ala Leu Val Glu Ser Gly Val Gly Val Lys
325 330 335 Val Ala Arg Ala Asp Leu Ile Gly Lys Arg Trp Leu Asp Ile
Val Val 340 345 350 Glu Leu Gly Phe Cys Ser Ser Arg Gly Gln Ala Arg
Arg Leu Ile Gln 355 360 365 Gln Arg Gly Leu Tyr Ile Asn Gln Glu Pro
Leu Ala Asp Glu Gln Ser 370 375 380 Ile Leu Asp Gly Thr Gln Leu Cys
Phe Asp Arg Tyr Val Leu Leu Ser 385 390 395 400 Gln Gly Lys Arg Lys
Lys Gln Val Ile Asp Leu Asn 405 410 9390PRTChlamydia trachomatis
9Ser Leu Thr Val Pro Val Ser Ala Tyr Leu Gly Phe Asp Pro Thr Ala 1
5 10 15 Pro Ser Leu His Ile Gly His Trp Ile Gly Ile Cys Phe Leu Arg
Arg 20 25 30 Leu Ala Ala Tyr Gly Ile Thr Pro Val Ala Leu Val Gly
Gly Ala Thr 35 40 45 Gly Met Ile Gly Asp Pro Ser Gly Lys Ser Val
Glu Arg Ser Leu Leu 50 55 60 Asp Gln Ala Gln Val Leu Asp Asn Ser
Lys Lys Ile Ala Ala Ala Leu 65 70 75 80 Ala Ser Tyr Leu Pro Gly Ile
Arg Ile Val Asn Asn Ala Asp Trp Leu 85 90 95 Gly Ser Leu Ser Met
Val Asp Phe Leu Arg Asp Val Gly Lys His Phe 100 105 110 Arg Leu Gly
Ser Met Leu Ala Lys Asp Val Val Lys Gln Arg Val Tyr 115 120 125 Ser
Glu Glu Gly Ile Ser Tyr Thr Glu Phe Ser Tyr Leu Leu Leu Gln 130 135
140 Ser Tyr Asp Phe Ala His Leu Phe Lys Glu His Asn Val Val Leu Gln
145 150 155 160 Cys Gly Gly Ser Asp Gln Trp Gly Asn Ile Thr Ser Gly
Ile Asp Tyr 165 170 175 Ile Arg Arg Arg Gly Leu Gly Gln Ala Tyr Gly
Leu Thr Tyr Pro Leu 180 185 190 Leu Thr Asp Ser Lys Gly Lys Lys Ile
Gly Lys Thr Glu Ser Gly Thr 195 200 205 Ile Trp Leu Asp Pro Ala Leu
Thr Pro Pro Tyr Glu Leu Phe Gln Tyr 210 215 220 Phe Leu Arg Leu Pro
Asp Gln Glu Ile Ser Lys Val Met Arg Thr Leu 225 230 235 240 Thr Leu
Leu Asp Asn Glu Glu Ile Phe Ala Leu Asp Glu Arg Leu Thr 245 250 255
Ser Asp Pro Gln Ala Val Lys Lys Tyr Ile Ala Glu Val Ile Val Lys 260
265 270 Asp Val His Gly Ser Glu Gly Leu Ala Gln Ala Gln Ala Ala Thr
Glu 275 280 285 Ser Phe Phe Ala Ser Lys Gly Lys Ser Ile Thr Glu Ala
Glu Leu Val 290 295 300 Ala Leu Val Glu Ser Gly Val Gly Val Lys Val
Ala Arg Ala Asp Leu 305 310 315 320 Ile Gly Lys Arg Trp Leu Asp Ile
Val Val Glu Leu Gly Phe Cys Ser 325 330 335 Ser Arg Gly Gln Ala Arg
Arg Leu Ile Gln Gln Arg Gly Leu Tyr Ile 340 345 350 Asn Gln Glu Pro
Leu Ala Asp Glu Gln Ser Ile Leu Asp Gly Thr Gln 355 360 365 Leu Cys
Phe Asp Arg Tyr Val Leu Leu Ser Gln Gly Lys Arg Lys Lys 370 375 380
Gln Val Ile Asp Leu Asn 385 390 10298PRTChlamydia trachomatis 10Met
Leu Lys Ile Asp Leu Thr Gly Lys Ile Ala Phe Ile Ala Gly Ile 1 5 10
15 Gly Asp Asp Asn Gly Tyr Gly Trp Gly Ile Ala Lys Met Leu Ala Glu
20 25 30 Ala Gly Ala Thr Ile Leu Val Gly Thr Trp Val Pro Ile Tyr
Lys Ile 35 40 45 Phe Ser Gln Ser Leu Glu Leu Gly Lys Phe Asn Ala
Ser Arg Glu Leu 50 55 60 Ser Asn Gly Glu Leu Leu Thr Phe Ala Lys
Ile Tyr Pro Met Asp Ala 65 70 75 80 Ser Phe Asp Thr Pro Glu Asp Ile
Pro Gln Glu Ile Leu Glu Asn Lys 85 90 95 Arg Tyr Lys Asp Leu Ser
Gly Tyr Thr Val Ser Glu Val Val Glu Gln 100 105 110 Val Lys Lys His
Phe Gly His Ile Asp Ile Leu Val His Ser Leu Ala 115 120 125 Asn Ser
Pro Glu Ile Ala Lys Pro Leu Leu Asp Thr Ser Arg Lys Gly 130 135 140
Tyr Leu Ala Ala Leu Ser Thr Ser Ser Tyr Ser Phe Ile Ser Leu Leu 145
150 155 160 Ser His Phe Gly Pro Ile Met Asn Ala Gly Ala Ser Thr Ile
Ser Leu 165 170 175 Thr Tyr Leu Ala Ser Met Arg Ala Val Pro Gly Tyr
Gly Gly Gly Met 180 185 190 Asn Ala Ala Lys Ala Ala Leu Glu Ser Asp
Thr Lys Val Leu Ala Trp 195 200 205 Glu Ala Gly Arg Arg Trp Gly Val
Arg Val Asn Thr Ile Ser Ala Gly 210 215 220 Pro Leu Ala Ser Arg Ala
Gly Lys Ala Ile Gly Phe Ile Glu Arg Met 225 230 235 240 Val Asp Tyr
Tyr Gln Asp Trp Ala Pro Leu Pro Ser Pro Met Glu Ala 245 250 255 Glu
Gln Val Gly Ala Ala Ala Ala Phe Leu Val Ser Pro Leu Ala Ser 260 265
270 Ala Ile Thr Gly Glu Thr Leu Tyr Val Asp His Gly Ala Asn Val Met
275 280 285 Gly Ile Gly Pro Glu Met Phe Pro Lys Asp 290 295
11102PRTChlamydia trachomatis 11Met Ser Asp Gln Ala Thr Thr Leu Lys
Ile Lys Pro Leu Gly Asp Arg 1 5 10 15 Ile Leu Val Lys Arg Glu Glu
Glu Ala Ser Thr Ala Arg Gly Gly Ile 20 25 30 Ile Leu Pro Asp Thr
Ala Lys Lys Lys Gln Asp Arg Ala Glu Val Leu 35 40 45 Ala Leu Gly
Thr Gly Lys Lys Asp Asp Lys Gly Gln Gln Leu Pro Phe 50 55 60 Glu
Val Gln Val Gly Asn Ile Val Leu Ile Asp Lys Tyr Ser Gly Gln 65 70
75 80 Glu Leu Thr Val Glu Gly Glu Glu Tyr Val Ile Val Gln Met Ser
Glu 85 90 95 Val Ile Ala Val Leu Gln 100 129PRTArtificial
SequenceSynthetic Construct 12Gly Tyr Lys Asp Gly Asn Glu Tyr Ile 1
5 138PRTArtificial SequenceSynthetic Construct 13Ser Ile Ile Asn
Phe Glu Lys Leu 1 5 149PRTArtificial SequenceSynthetic Construct
14Arg Pro Gln Ala Ser Gly Val Tyr Met 1 5
* * * * *